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Prostate cancer is a principal cause of illness and death among men in the United States and Western 
Europe. Autopsy series have demonstrated small prostatic carcinomas in up to 29 percent of men 30 to 40 
years of age and 64 percent of men 60 to 70 years of age. Moreover, the risk of prostate cancer is 1 in 6 and 
the risk of death due to metastatic prostate cancer is 1 in 30 (1). Curative treatment is usually prostatectomy 
or radiation to remove or destroy the cancerous cells that are still confined within the prostate capsule (fig. 
1). However, many patients are not cured by this form of therapy and their cancer recurs, or they are diag-
nosed after the cancer has spread to distant sites. Curative treatment of prostate cancer is only possible 
when tumor cells are predominantly confined to the prostate (1). 
MECHANISM OF ANDROGEN ACTION
Why do prostate cancer cells need androgens to grow and survive (2) ? Prostate cancer growth is depend-
ent  on the ratio of proliferating cells to those dying. Androgens are considered as the main regulator of this 
ratio by both stimulating proliferation and inhibiting apoptosis. So it could be concluded that, prostate cancer 
depends on a crucial level of androgenic stimulation for growth and survival. Androgen blockage causes re-
gression of prostate cancer because without androgen, the rate of cell proliferation is lower and the rate of 
cell death is increased, leading to extinction of these cells (3). Testosterone - which is the main circulating 
androgen — is secreted primarily by the testes, but is also synthesized by peripheral conversion of adrenal 
steroids (2). 90% of the free testosterone entering the prostate cells is converted to dihydrotestosterone 
(DHT) by the enzyme 5α-reductase (SRD5A2). DHT is the more biologically active hormone, possessing 
five-fold higher affinity for the androgen receptor (AR) than does testosterone. DHT binds to the androgen 
receptors in the cytoplasm, leading to the phosphorylation, dimerization, and subsequent translocation into 
the nucleus, thereby binding to the androgen-response elements within the DNA, with resultant activation of 
genes involved in cell growth and survival (2). Almost all metastatic prostate cancers initially require testos-
terone for growth, and the use of androgen deprivation as a first-line therapy for metastatic prostate cancer 
has been recognized for more than 60 years (4, 5). Hormone deprivation is achieved by surgical (orchiec-
tomy) or medical (luteinizing hormone-releasing hormone agonists, anti-androgens) castration. Furthermore, 
simultaneous administration of therapies designed to block adrenal androgen production or the binding of 
residual androgens to the androgen receptor by synthetic anti-androgens has been recommended by many 
studies (6, 7). Androgen deprivation therapy leads to remissions lasting 2 to 3 years; however, virtually all 
patients progress to a clinically androgen-independent state resulting in death in 16 to 18 months (8-12).
MECHANISM OF AIPC DEVELOPMENT
Androgen-independent prostate cancer (AIPC) is a lethal form of prostate cancer that progresses and metas-
tasizes. There are several pathways, which have been shown to be responsible for the development of 
AIPC. These pathways gives us deep insights into the mechanisms of androgen action and provides us a 
deeper understanding of the mechanisms by which cancer cells subvert normal growth control and escape 
attempts to treat the prostate cancer (13). Deeper understanding of these pathways is the first step towards 
developing new therapies against this lethal form of prostate cancer. These mechanisms are demonstrated 
in Fig.2 and include:
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FIGURE 1. Represents clinical states of prostate cancer. Curative therapy is available only for the localized disease when tumor cells are 









































































































































































































The hypersensitive pathway 
One way in which prostate cancer cells surpass the effects of androgen blockade is by developing the ability 
to use very low levels of androgens for (14-16), which means that they do not become androgen independ-
ent in the classic sense, but rather castration independent (13).There are several mechanisms which could 
explain response to lower levels of androgens. 
One of these responsible mechanism is enhanced expression of the androgen receptor, which eventually 
allows enhanced binding of ligand. The existence of this pathway is supported by various studies of hor-
mone refractory tumors that show increased expression of androgen receptor as compared to androgen-
dependent tumors (14, 17-22). Elevated production of androgen receptor is caused either due to gene ampli-
fication or mutations through selective pressure of the androgen-depleted environment, which eventually 
causes the cells with fewer androgen receptors to die off and leading to clonal expansion of cells expressing 
more androgen receptor. Chen en colleagues have shown that AR gene expression was up regulated during 
the progression from androgen-dependent to castration-independent growth (14). Furthermore, they also 
showed that androgen-independent cells require 80% lower concentrations of androgen than androgen-
dependent cells for growth (14).
Increased androgen receptor sensitivity to androgens has been suggested  as another important mechanism 
for castration resistance (15). In support of this, Gregory and colleagues have shown that recurrent prostate 
tumors posses high level expression of the androgen receptor, increased stability of the androgen receptor, 
and enhanced nuclear localization of the androgen receptor, which is associated with an increased sensitiv-
ity to the growth-enhancing effects of dihydrotestosterone (15). 
A third hypersensitive mechanism considered to be important is increased local production of androgens by 
prostate cancer cells themselves, which  most likely occurs due to increased rate of conversion of testoster-
one to dihydrotestosterone via an increased activity of 5-alpha-reductase (2). There are various evidences 
that are in support of this mechanism which includes (a) ethnic groups with higher levels of 5-alpha-
reductase activity are at a higher chance of development of prostate cancer (23); (b) after the initiation of the 
androgen ablation therapy, serum testosterone levels decrease by 95%, but concentration of dihydrotestos-
terone in prostatic tissue reduces by only 60% (24); and (c) genes involved in steroid biosynthesis have 
been shown to be overexpressed in recurrent human prostate tumors (20).
Promiscuous Receptor
The wild-type androgen receptor is stimulated only by testosterone and dihydrotestosterone, and it has been 
shown that specificity of androgen receptor is broadened by mutations.The majority of mutations are found 
to be clustered in the ligand-binding domains leading to binding promiscuity of androgen receptor (25, 26). 
Due to these mutations the androgen receptor can be activated by nonandrogenic steroid molecules, which 
are normally present in the circulation as well as antiandrogens (2, 14, 27-32). Such mutations have been 
demonstrated to be more frequent in androgen-independent prostate cancer cells and it form the basis of 
antiandrogen withdrawal syndromes in which 10% to 30% of patients treated with long-term antiandrogens 







































FIGURE 2. Pathways to androgen independence. (a) Hypersensitive pathway : Enhanced expression of the androgen receptor leading to 
enhanced ligand binding or enhanced conversion of testosterone to more potent dihydrotestosterone (DHT) by 5α-reductase.(b) Promiscuous 
pathway : AR(Androgen receptor) activated by non-androgenic molecules  present in the circulation leading to the activation of AR.(c) Outlaw 
pathway : Activation  of receptor tyrosine kinases (RTKs) leading to downstream activation of either AKT(protein kinase B) or the mitogen-
activated protein kinase (MAPK ), which leads to phosphorylation and activation of AR. (d) Bypass pathway : Activation of the parallel survival 
pathways, thus obviating the need for AR or its ligand.(e) The lurker cell pathway : Presence of prostate cancer stem cells that continually 
resupply the tumor cell population, despite therapy. Although these cancer stem cells remain a small percentage of the actual percentage of the 
tumor, they are not affected by androgen-depletion therapy. “Adapted from Nature reviews cancer 1:34-45, 2001”
Outlaw Pathway
It is known that stimulation of androgen receptor can be achieved by ligand dependent binding of nonsteroid 
molecules or via the activation of downstream signaling of the androgen receptor by ligand independent 
mechanisms. Such type of activation has been defined as outlaw activation (2, 27, 28, 37). Deregulation of 
growth factors, for example insulin-like growth factor, keratinocyte growth factor, and epidermal growth fac-
tor, and cytokines, including IL-6, have been shown to directly phosphorylate and stimulate the androgen re-
ceptor (38, 39). It has been shown that androgen receptor dependent genes can be activated by deregula-
tion of signal transduction pathways (40,41). HER-2/neu receptor overexpression activates androgen recep-
tor–dependent genes in the absence of a ligand (40,41). Furthermore, the overactivity of outlaw pathways 
demonstrates the potential importance of tumor-microenvironment interactions in the development of 
castration-independent growth (42,43). Paget in his famous theory hypothesized that a ‘‘fertile soil’’ was re-
quired for the successful growth of cancer metastases (44). The interaction of prostate cancer cells with 
bone stromal cells, osteoblasts, and osteoclasts and bone extracellular matrix, leads to the deregulation of 
multiple growth factors that the prostate cancer cells can utilize to become androgen independent (2).
Co-activators and co-repressors
A large number of co-activators and co-repressors have been identified that are  involved in the regulation of 
androgen receptor driven transcription (45). Imbalance between co-activators and co-repressors have been 
shown to influence androgen receptor activation, but the precise mechanisms are unknown (2, 46-49). An 
increased level of co-activators has been well identified in androgen-independent disease (46, 50-52). Co-
activator proteins enhances the activity of the androgen receptor to alternative ligands, thereby  sensitizing 
the receptor to lower levels of native and nonnative ligands, leading to ligand-independent activation(46).
Activation of bypass Pathways
Androgen receptor pathway can be completely bypassed, and prostate cancer cells can develop the ability 
to survive independent of ligand-mediated or non-ligand-mediated androgen receptor activation. Modulation 
of apoptosis is the best-known bypass mechanism. In androgen-dependent prostate cancer cells, androgen 
receptor activation stimulates cell proliferation but depletion of androgen leads to apoptosis of these cells. 
Androgen-independent prostate cancer cells have been shown to possess higher levels of anti-apoptotic 
molecules (53-56). Inactivation of the tumor suppressor gene phosphatase and tensin homologue (PTEN) 
leading to subsequent activation of Akt is one of the best known way in which AIPC cells escape apoptosis 
in an androgen-depleted environment (28). Another suggested bypass mechanism is the neuroendocrine 
differentiation of prostate cancer cells (28). Neuroendocrine cells exhibits a low rate of proliferation and are 
more prevalent in androgen refractory prostate cancers (28). They also secrete neuropeptides, which leads 
to increase in the proliferation of neighboring cancer cells, ultimately leading to progression in a low-
androgen environment (28).
Prostate Cancer Stem Cells
In contrast to the stochastic model of tumorigenesis, the stem cell model of cancer postulates that only a 
rare subset of tumor cells are tumorigenic (54). Such population of cells comprising 0.1% of prostate tumors, 
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have been shown to be CD44+/alpha2 beta1hi/CD133, which do not express androgen receptors, and is 
thought to be enriched in prostate cancer stem - or progenitor cells (57). The prostate cancer stem cells in 
the androgen-depleted environment continually resupply the tumor cell population, and these cancer stem 
cells are not effected by the androgen-depletion therapy. Differentiation of these cancer stem cells into andro-
gen dependent and independent cells results in the formation of heterogenous androgen receptor phenotype 
observed in AIPC patients (12).
DEVELOPMENT OF TARGETED APPROACHES AGAINST PROS-
TATE CANCER METASTASIS
Several molecular abnormalities have been identified that can lead to prostate cancer progression and devel-
opment of androgen independent state. Many of these targeted therapies are now under various phases of 
clinical development (13, 58). Although most previous work have been focused on the androgen receptor but 
it is likely that several other molecular targets leads to the development of prostate cancer progression and 
androgen independent state (13). Development of these therapies requires the recognition that some of 
these targets may be relevant to the entire disease spectrum of prostate cancer but others may only be rele-
vant for specific stages of prostate cancer.  Many of these hypotheses-driven therapies are undergoing pre-
clinical and clinical testing but, still there is a clear need for a better identification and selection of the specific 
patient population that will experience maximum benefit from specific molecular targeted approach (58).May 
be in the near future, it will be possible to determine the predominant mechanism of  resistance in a tumor 
as it progresses during treatment and then apply that knowledge for the selection of the appropriate targeted 
therapy , with the goal of turning prostate cancer into a chronic disease. (58)
MOLECULAR MECHANISMS IN PROSTATE CANCER INVASION
Local invasion is one of the earliest steps in metastasis. To become invasive, the malignant cell should have 
the ability to downregulate its cell–cell contacts and alter cell–matrix adhesive characteristics, become motile 
and acquire the ability to degrade the extracellular matrix (ECM) (59). As soon the malignant cell has de-
graded the basement membrane, then it must enter the vascular or lymphatic circulation by breaching the 
endothelial barriers. Then the cancer cell should have acquired the ability to migrate via the blood or lym-
phatic circulation and should  have the ability to arrest at a secondary endothelial site before binding to the 
endothelium, extravasating and then transmigrate through the endothelial layer to reach the interstitium, 
where it  could have various fates as outlined in the figure 3 (60). There are various molecular mediators that 
have been shown to mediate the local invasion and dissemination of these prostate cancer cells. Some of 
well-known mechanisms are:
Epithelial to mesenchymal transition (EMT) in prostate cancer
In the normal prostate gland, epithelial cells have restricted migratory capability because the basal cells in-
side the lumen attach to the basement membrane and to each other forming a layer of interconnected cells 
with apical-basal polarity. Cell-to-cell adhesion in this epithelial layer is maintained by several types of junc-
tions, such as adherens- and tight junctions. These junctions are composed of protein complexes of cell ad-
hesion molecules (CAMs), such as cadherins. EMT is a cellular process through which epithelial cells lose 
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their epithelial characteristics like cell polarity and cell-cell junctions. During this epithelial to mesenchymal 
transition cells undergo changes in cytoskeleton and shape leading to acquirement of mesenchymal charac-
teristics resulting in gain of migratory and invasive properties (61). Disruption of the E-cadherin-catenin adhe-
sion complex is a key step in these processes. In prostate cancer, one of the most important features of cells 
undergoing EMT is cadherin switching, whereby E-cadherin (expressed in normal epithelial cells) is down-
regulated and N-cadherin (expressed in mesenchymal cells) is upregulated. Higher gleason grade prostate 
cancers have lower E-cadherin and higher N-cadherin expression, as compared to prostate cancer in pa-
tients with lower gleason grade disease (62-64). Decreased catenin expression has been also shown to be 
associated with decreased expression of E-cadherin, and with higher grade prostate cancer (65). In prostate 
cancer, one important signaling axis that can support EMT (in addition to effects on proliferation) is the HGF 
receptor, MET. Expression of the MET receptor is associated with disease progression and MET inhibitors 
are actively tested in prostate cancer clinical trials (66)
Prostate cancer invasion: Roles of proteases
Matrix metalloproteinases and serine proteinases (for example urokinase- type plasminogen activator) are 
the most important families of proteinases that have been shown to be most associated with degradation of 
extracellular matrix in prostate cancer. It has been shown that primary prostate tumor tissues posses higher 
levels of MMP-9, and also the ratios of of MMP-2/-9 to tissue inhibitor of metalloproteinases-1 (TIMP-1) are 
increased as compared to normal prostate epithelium. Also, the levels of MMP-9 and the ratios of MMP-2/-9 
are increased in patients with high gleason grade prostate cancer, which is  associated with poorer patient 
survival (67-69). Furthermore, It has been shown that that loss of TIMP-1 is correlated with upregulation of 
MMPs in malignant human prostate cancer tissues(70). Patients with metastatic prostate cancers are ob-
served to have high concentrations of MMP-2 and MMP- 9 in their plasma (71). MMP-12 downregulation us-
ing RNAi  approach reduced the invasiveness of PC3 cells by reducing degradation of Type I collagen in the 
bone, which supports the fact that MMP-12 also participates in bone-tropic metastasis(72).
Adhesion signaling in prostate cancer migration 
Cell migration is a dynamic process mediated by Focal adhesion (FA) signaling. Focal adhesions are the re-
gions where integrins, in large dynamic protein complexes establish a signaling link between the ECM and 
actin cytoskeleton. Integrin-mediated ECM adhesion leads to activation of downstream pathways involved in 
gene regulation, proliferation, apoptosis, cell survival, polarity, actin dynamics and cell migration (73, 74). 
The predominant integrins present in normal prostate epithelial cells are alpha5 beta1, alpha6 beta1, alpha6 
beta4, alpha V beta3 and alpha3 beta1 (75). Lee et al., has showed that levels of beta1 integrins and 
integrin-induced autophosphorylation of FAK are increased in prostate cancer cells in primary prostate can-
cer and lymph node metastases, which suggests that beta1 integrin activation occurs in metastatic progres-
sion of prostate cancer (76). It suggests that alterations in integrin composition and function can thus affect 
migration of prostate cancer cell through modulation of FAK function. Furthermore, overexpression of FAK 




FIGURE 3.  The metastatic cascade (a) Tumor cells escape from the primary tumor and then arrest at the secondary metastatic sites (b) 
Cancer cells can have various fates following their arrival at the secondary metastatic sites. At secondary sites, cancer cells can exist in 
various forms like solitary cells, micrometastasis and vascularized macrometastasis. The balance between the proliferation and survival 
governs their fate at each step. Cells, which adapt better to the foreign microenvironment (in line with Pagets seed and soil hypothesis) 
survive, proliferate and progresses to form vascularized macrometastasis.The cells where proliferation is balanced by apoptosis stays 
dormant, and those cells die where the balance tilts in favour of apoptosis. “Adapted from Nature Rev Cancer 2:563-72, 2002”
MODELS TO STUDY PROSTATE CANCER METASTASIS
As our understanding of prostate cancer becomes more comprehensive, the need for more sophisticated 
and accurate models increases (78). Experimental therapeutics targeting specific tumor-specific molecules 
must be validated in well-characterized models that enable the testing of the experimental hypothesis. By 
establishing models that replicate human prostate cancer progression more closely and by asking more dis-
ease specific questions with such models, animal models will continue to play an important role in validating 
novel cancer targets and evaluating putative cancer therapies (78). Three dimensional extracellular matrix 
models and animal based models, are being utilized to replicate and model the various steps of metastatic 
cascade. Figure 3 gives an overview of the steps involved in metastasis cascade. Basic understanding of 
the dynamics of metastasis cascade is the key to the development of novel models and to the development 
of novel anti-cancer therapies.  In 3D based assays prostate cancer cells are either grown inside the matrix 
or plated on the top of the matrix to model the complex processes of growth, local invasion and migration. 
Also these 3D based models provide an ideal platform to study the complex interactions between the cancer 
cells and the extracellular matrix (79). In animal based models, cancer cells are injected to form a primary 
tumor orthotopically (in the prostate) or at other, more easily accessible sites (e.g. subcutaneous) and tumor 
growth as well as metastasis is monitored. Alternatively, tumor cells are injected directly into the circulation 
to model the later phases of the metastatic process such as extravasation and metastatic colonization. 
These assays are called, respectively, spontaneous or experimental metastasis assays (80, 81) and the end 
point of both assays is the formation of visible metastases at a secondary site. These assays have led to the 
identification of many molecular alterations in cancer cells that can contribute to their ability to metastasize, 
and selective targeting of these tumor cell specific alterations is the basis of molecular targeted approach 
(82-87). These models constitute the major preclinical tool required for the further development of new thera-
peutic strategies. Xenografts are the most commonly used models in drug development and are able to 
maintain several biological properties of the human tumors they are derived from, particularly when orthotopi-
cally transplanted. Osteoblastic bone metastases can also be modeled (78). Non-invasive methods of imag-
ing have been recently developed to significantly reduce the number of mice required and have improved 
the follow up of tumor growth and response to therapy in these models. Genetic models are very useful for 
target validation, but have not yet been extensively used for drug evaluation. Finally, some models are more 
relevant for the study of specific pathways as androgen receptor signaling, or bone metastases develop-
ment, and others are useful in developing strategies targeting prostate cancer stem cells or mechanisms of 
resistance to chemotherapy or radiotherapy (78).
The modern drug development technologies increase the number of candidate therapeutics and subse-
quently increase the costs for preclinical and clinical testing. Mouse models are time, labor, and finance in-
tensive and current limitations have hampered the transition of scientific findings from these models to hu-
man clinical trials. Moreover, while the vast contribution of mouse models to advancing our understanding of 
cancer biology is indisputable, there have been ongoing concerns about the value of mouse models for pre-
dicting drug efficacy and usefulness in humans, and the predictive value of tumor xenograft models in can-
cer research is still a matter of debate. Thus, the development of faster and cheaper animal model systems 
and improvements in the ability of preclinical models to predict clinical efficacy can have a high impact by 




Metastasis is a major cause of death and morbidity in patients with neoplastic disease, but one major obsta-
cle in the progress of prostate cancer studies has been the limited availability of relevant preclinical models 
(78). Current limitations of these models have hampered and delayed the transition of scientific findings  to 
clinical trials. The ideal prostate cancer model is one that reproduces and replicates the natural history of the 
prostate cancer, and able to generate long-term spontaneous metastases to lymph nodes, lungs and bones. 
Such ideal prostate cancer model does not exist (78). However, models for investigating key steps in the 
metastatic cascade have been developed and can be further improved. The greatest challenge of the post 
genomic cancer drug discovery is to develop mechanism based agents that act on the key biological tumor 
specific processes and then sequentially to test the hypothesis that such tumor specific agents are indeed 
more potent and more specific than the current available generation of anti cancer drugs. There is lot of criti-
cism regarding the value of two-dimensional based in vitro models in anti-cancer drug target discovery (88). 
Facing this criticism, the cancer researcher is continuously challenged to develop novel models that could 
enable us to study disease specific question in a setting that nearly recapitulates the natural history of meta-
static process. The development of better anti-cancer targets continues, and it is now evident that selection 
of the appropriate disease models is of utmost importance during the pre-clinical drug discovery process 
when investigating biological processes like invasion, dissemination and metastatic colonization. One of the 
most important thing is to use the right models to ask the right questions about the right therapies (78).
Based on this background the specific aims were (as schematically outlined in figure 4) :
- To develop novel 3D in vitro and whole organism-based high-throughput models of (prostate) cancer pro-
gression that are suitable for both compound as well as RNA-interference screening approaches.
- To Identify/validate novel candidate genes playing a significant role in prostate cancer progression.
16
OUTLINE OF THESIS
The ultimate aim of this thesis is the identification and validation of novel candidate genes playing a signifi-
cant role in the prostate cancer metastasis. For that purpose, we established imaging based automated in-
vitro and in-vivo models to study growth, migration, invasion and dissemination of (prostate) cancer. First, 
we established an automated 3D in vitro assay to study growth, local invasion and migration of cancer cell 
spheroids in an extracellular collagen matrix. The development of this assay is described in chapter 2. For 
prostate cancer, and most other solid cancers, it is necessary to develop whole organism based bio-imaging 
models to screen for novel candidate target genes which can deepen our understanding of the mechanism 
underlying metastatic progression. In chapter 3, we developed an automated bio-imaging model of cancer 
progression using xenotransplantation in zebrafish embryos. In chapter 4, current state of art in prostate 
cancer treatment is discussed. Here, we discuss emerging new molecular targets and the potential clinical 
applications of combining radiotherapy with these molecular targeted agents for the treatment of prostate 
cancer. It will be important to find more drug targets and this is what we describe in following two chapters. 
In chapter 5, we describe the identification of SYK as a novel candidate prostate cancer target gene derived 
from a RNA-interference screen exploiting the zebrafish xenotransplantation model. Next to the RNA-
interference screening, focused research has been conducted on previously identified novel candidate 
genes. In chapter 6, we describe MST1R as a dominant factor in prostate cancer progression. Finally chap-
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FIGURE 4. Schematic representation of the specific aims/outcomes of the thesis.
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ABSTRACT
Cell spheroids (CS) embedded in 3D extracellular matrix (ECM) serve as in vitro mimics for multicellular 
structures in vivo. Such cultures, started either from spontaneous cell aggregates or single cells dispersed in 
a gel are time consuming, applicable to restricted cell types only, prone to high variation, and do not allow 
CS formation with defined spatial distribution required for high-throughput imaging. Here, we describe a 
novel method where cell-polymer suspensions are microinjected as droplets into collagen gels and CS for-
mation occurs within hours for a broad range of cell types. We have automated this method to produce CS 
arrays in fixed patterns with defined x-y-z spatial coordinates in 96 well plates and applied automated imag-
ing and image analysis algorithms. Low intra- and inter-well variation of initial CS size and CS expansion indi-
cates excellent reproducibility. Distinct cell migration patterns, including cohesive strand-like- and individual 
cell migration can be visualized and manipulated. A proof-of-principle chemical screen is performed identify-
ing compounds that affect cancer cell invasion/migration. Finally, we demonstrate applicability to freshly iso-
lated mouse and human tumor biopsy material - indicating potential for development of personalized cancer 
treatment strategies.
INTRODUCTION
Cells grown under classical 2D culture conditions behave differently from the same cell types grown in vivo. 
In addition to soluble factors produced in the in-vivo microenvironment, differences in cell shape, intercellular 
contacts, and connections to ECM have striking effects on gene expression, cell survival, proliferation, differ-
entiation, cytoarchitecture, and migration. Various systems have been developed to culture cells within 3D 
ECM environments, aimed at more closely mimicking the in-vivo context (1,2). Several of these systems pro-
duce 3D cell aggregates in which, after compaction, depletion of oxygen, nutrients, and growth factors oc-
curs in the core, leading to cell heterogeneity depending on the position in the resulting CS (3,4). Multistep 
methods are used in which aggregates are allowed to form spontaneously and, following a compaction 
phase, can subsequently be transferred to a 3D ECM. The best-known example of this approach is the 
“hanging drop assay” that was developed to create embryoid bodies from ES cells and has also been ap-
plied to cancer cell lines to produce tumor-like structures (5,6). Alternative methods involve mixing of single 
cell suspensions with a solidifying ECM, resulting in individual cells that eventually form spheroids randomly 
within a 3D ECM structure (7), or seeding polymeric scaffolds with cell/ECM suspensions (2). Cell behavior 
in 3D cultures is controlled by chemical (composition) and physical (rigidity, cross-linking) properties of the 
gel. Natural ECM proteins can be used such as collagen, fibrinogen, or the laminin-rich matrigel to represent 
the in-vivo ECM composition most relevant to a given cell type. More recently, synthetic polymers have been 
developed for 3D CS culture environments although it remains to be established how well these support a 
variety of cell behavioral outputs, including cell migration (8). Collagen type 1 is an abundant polymer in 
ECM in vivo, and it is widely used for 3D cultures. Various physical properties of the collagen gel, such as 
rigidity and pore size modulate stem cell differentiation, cancer growth, and cell migration (9-11). Cells can 
use various migration strategies in 3D environments, including mesenchymal or amoeboid individual cell mi-
gration modes or collective invasion strategies, depending on properties of the cells and of the matrix (10). 
Changes in matrix pore size can force cells to adopt alternative migration strategies or - if too extreme - 
pose a barrier to cell migration. Importantly, cells can modify the ECM by physical deformation and proteoly-
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sis, to overcome such barriers (12). Chemical compound screens as well as RNAi screens for various types 
of cellular functions, including survival, growth, differentiation, and migration are mostly performed in 2D cul-
ture conditions. Methods to analyze cells in 3D based on the hanging-drop assay are labor and time inten-
sive; are limited to cell types that are cohesive and aggregate spontaneously; and are prone to high variabil-
ity between experiments due to variation in aggregation and compaction time and CS size. Alternative meth-
ods in which single cell suspensions are mixed with soluble ECM substrates that are subsequently allowed 
to form a gel are relatively easy to perform but also have several major disadvantages: formation of CS de-
pends on the ability of a cell type to survive and proliferate as single cells in low adhesion conditions for ex-
tended periods; CS formation is time consuming; CS show a large variation in size; and CS form at random 
locations, which is disadvantageous for imaging purposes. To allow for CS formation that is relatively fast 
and easy, highly reproducible, and overcomes the disadvantages described above we have developed a 
novel method where cell-polymer suspensions are microinjected into multiwell plates containing a collagen 
gel. This method has been automated to produce CS arrays with highly reproducible properties in large 
quantities in 96 well plates. We use this system to visualize distinct 3D migration strategies and regulation of 
those strategies by ECM properties and actomyosin contractility. We demonstrate applicability in high-
throughput screening platforms in a chemical screen for compounds that affect breast cancer invasion/
migration. Finally, we apply the method to cell suspensions derived from fresh tumor biopsies, which opens 
the possibility to test therapeutic strategies on freshly isolated material from individual patients.
RESULTS
Development and characterization of the method 
To design a protocol that rapidly produces CS with highly reproducible characteristics, we developed a novel 
method based on microinjection. For the microinjection method we mixed cells with polyvinylpyrrolidone 
(PVP), which is an inert (hydrophilic) water-soluble synthetic polymer, also used as emulsifier, food-additive 
(E1201) and as solubilizing agent for injections (13). In our application it was used to delay cell sedimenta-
tion within the capillary needle. Furthermore, in our experience cells rapidly disperse in the absence of PVP 
while cells injected in the presence of PVP remained localized (e.g. trapped by the polymer) at the site of 
injection, allowing time for aggregation and CS formation. We first compared our method to the established 
hanging drop assay (5). Twenty µl drops containing 5x103 GEß1 cells were used to create hanging drops in 
an inverted 10 cm dish (Fig. 1a). The time required to form cell aggregates was 24h. These cell aggregates 
were transferred to agarose-coated dishes where they formed tightly packed spheroids over a period of 48h. 
Next, the spheroids were embedded in 2.4 mg/mL collagen solution that was subsequently allowed to solid-
ify. For microinjection, GEß1 cells were suspended in 2% PVP, loaded into a pulled glass needle, and ~80nL 
droplets containing ~1x104 cells were injected directly into preformed 2.4 mg/mL collagen gels where they 
formed tightly packed spheroids within 1h (Fig. 1a). Microinjection-derived CS at 24h post-injection and 
hanging-drop-derived CS at 96h post initiation (24h in collagen) displayed similar cell migration the following 
days (Fig. 1b). Microinjection-derived CS were also established from 4T1 mouse breast carcinoma cells 
where E-cadherin  staining marked cell-cell contacts within the first day post-injection that were maintained 
for at least 96h (Fig. 1c). CS derived by microinjection of different cancer- or non-cancerous cell types al-
lowed analysis of various distinct motile strategies in 3D (Fig.1d). Cell types that do not typically form cell-
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FIGURE 1.Characteristics of microinjection-derived spheroids. A, Comparison of hanging-drop and microinjection method for GEß1 cells. B, 
Migration of GEß1 cells from hanging-drop and microinjection-derived spheroids. C, E-cadherin staining in spheroids at indicated timepoints 
post-injection for 4T1 cells. D, Different modes of cell migration from spheroids for indicated cell types showing individual (top row) and 
cohesive strand migration (bottom row). E, Modulation of cell migration modes by alterations in collagen gel network (left and middle) or 
interfering with cytoskeletal network (right image, ROCK inhibitor). Arrowheads indicate cohesive migration strands; arrows indicate individual 
migrating cells. Scales, 120 µm.
cell contacts in 2D cell culture (and that are typically difficult to study in 3D using the hanging-drop-, liquid 
overlay-, or other assays in absence of additives like matrigel (14,15) such as MTLn3 and MDA-MB-231 
breast cancer cells and HT1080 fibrosarcoma cells, displayed amoeboid (MTLn3)or mesenchymal (HT1080 
and MDA-MB-231) movement of individual cells. On the other hand, 4T1 breast cancer, and human micro-
vascular endothelial cells (HMEC) that grow as islands in 2D culture, invaded as cohesive strands into the 
collagen matrix.ECM rigidity influences cell behavior in 3D and the actin cytoskeleton is believed to be essen-
tial for sensing and responding to such physical ECM properties (12). We used these CS to study the effect 
of alterations in ECM network composition or intracellular cytoskeletal network properties on migration strate-
gies in 3D. Lowering ECM rigidity by decreasing collagen concentration from 2.5 to 0.25 mg/mL or lowering 
cytoskeletal tension by application of a ROCK inhibitor, both caused a switch from cohesive strand invasion 
to individual cell migration in 4T1 cells (Fig. 1e). This suggests that tension exerted on cell-cell adhesion 
structures either from outside or inside the cell is required for cohesive 3D movement. Altogether, these re-
sults demonstrate that the microinjection method produces CS for 3D growth and migration studies rapidly 
(hours versus days), conveniently (one step), with a broad spectrum of cell types including those that are 
incompatible with previous methods, and displaying a variety of migration patterns.
Method automation
Since this method has the potential to rapidly create CS with high reproducibility for large- scale analysis in 
3D ECM of cell growth and migration/invasion we set up a procedure to automate the CS formation process. 
For this purpose, a 96 well plate containing 60 µL collagen gel per well was placed on a motorized stage and 
the glass needle containing the cell/PVP suspension described above was placed vertically in a motorized 
micromanipulator above the stage (Fig. 2a). After calibration of needle and 96-well plate using camera vision 
from under the stage, a computer script was used to automate the injection process with various 
macros.With this set up, cell droplets were injected resulting in spheroids of ~300 µm diameter (Movie S1). 
To increase reproducibility, using commercial needles reduced needle tip diameter variance and gels were 
prepared from a single large batch of collagen isolated in-house from rat-tail. Various layouts of injection pat-
terns were tested. A hexagonal pattern of 19 spheroids spaced at 1.2 mm started to show interaction be-
tween migration strands of CS at day 4 but a less dense hexagon pattern of 7 spheroids at 2 mm spacing 
provided sufficient spacing for 96h analysis of CS migration (Fig. 2b,c). Visual inspection indicated reduced 
CS migration on the most outer rows and columns of each plate, pointing to edge effects. We therefore 
chose to exclude these wells in all further experiments. We determined reproducibility in all other wells and 
detected no significant intra- or inter-well variation in initial CS size (ANOVA, P>0.5) or CS expansion over 
~92h (ANOVA, P>0.5) (Fig.2d). These data demonstrate that the microinjection method can be automated to 
create with high reproducibility and predefined x-y-z coordinates CS arrays in 96 well plates. Such properties 
make this protocol ideal for automated imaging strategies.
Application of the method to automated drug screens
A proof of principle drug screen was performed to test the applicability of this procedure to automated high-
throughput drug screening assays (HTS). 4T1 CS were generated and various previously described inhibi-
tors, including AG1478 (EGFR), PP2 (Src), ML-7 (MLCK), Y-27632 (ROCK), NSC23766 (Rac), SB-431542 
(TGFβR activin-like kinases), AG-82 (EGFR), LY-294002 (PI3K), JSI-124 (STAT3) were added one hour later 
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FIGURE 2. Automated production of spheroid arrays. A, Automated injection system (left) and cell/PVP suspension in needle during injection 
(right). B, Bottom view of multiple wells with 4T1 spheroid arrays 96 hours post-injection. Scale, 10mm. C, Upper row shows stitched 
brightfield images showing spheroid arrays at indicated timepoints. Scale, 1 mm. Bottom row shows cell migration from single bright-field 
images of spheroids marked by dashed rectangle in upper row. Scale, 100 µm. D, Mean and SD for initial spheroid size 4h post-injection 
(black bars) and CS migration over ~4 days determined from outline of migration strands (grey bars) obtained from all 7 spheroids /well for 
indicated wells of a 96-well plate.
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FIGURE 3. Results from a drug screen performed on 4T1 cells in a 96 well plate. A, DIC images showing tumor cell migration in the 
presence of indicated inhibitors at indicated timepoints (scale = 100 µm). B, Top 2 rows, rhodamine-phalloidin staining and thresholding for 
indicated wells at 4 dpi (columns correspond to treatments from A; rows represent duplicates); bottom row, zoom in on well D2 (Ctr), D4 
(PP2), and D10 (JSI-124). Scale, 1 mm. C, effect of indicated inhibitors on CS migration over ~4 days determined from outline of migration 
strands derived from DIC images in A (mean and SD for 14 spheroids derived from 2 wells is shown). D, Quantification of data derived from 
automated analysis of fluorescent images shown in B (mean and SD for 14 spheroids derived from 2 wells is shown).
at different concentrations (4, 10, 20 µM) in duplicate. Effects on cell migration could be clearly observed by 
DIC imaging after 2 and 4 days for ML-7 and JSI-124 (Fig.3a). For automated imaging and image analysis 
protocols, we labeled the actin cytoskeleton at day 4 of all 10 µM treatments and controls (Fig.3b). This al-
lowed automated capture of Z-stacks that were converted to maximum projection images, thresholded, and 
used for automated multiparameter analysis including Feret’s diameter and circularity. Visual inspection and 
manual assessment of Feret’s diameter from DIC images at day 0 and 4 demonstrated that initial CS size, 
CS expansion, and inhibition of invasion by ML-7 and JSI-124 were highly reproducible (Fig. 3a,c). Auto-
mated image analysis fitted well with these data showing that ML-7 and JSI-124 caused significantly re-
duced Feret’s diameters (p<0.05) (Fig.3d). For JSI-124 this correlated with increased circularity (p<0.05) in 
agreement with inhibition of invasion and a remaining round CS. The extremely low values observed for ML-
7 (Fig. 3d) despite the fact that a CS was observed by DIC (Fig.3a) can be explained by ML-7-induced loss 
of filamentous actin fibers causing reduced staining in this particular method. Alternative staining procedures 
should lead to improvement and compatibility with real-time analysis. Nevertheless, the reproducibility of the 
injection procedure (Fig. 2 and 3) combined with the similarity between visual inspection and automated im-
aging (Fig. 3c,d), demonstrates that this automated injection system can be coupled to fully automated imag-
ing and image analysis methodology that is accurate and reproducible.
Compatibility of the method with primary biopsy material
We determined if this methodology is compatible with freshly isolated biopsy material. First, a cell suspen-
sion was generated from 4T1-GFP orthotopic breast tumors in mice using collagenase- treatment. In con-
trast to alternative methods, the microinjection method circumvents any 2D tissue culture steps, which may 
cause altered cell behavior (16-20). Following injection, these cells rapidly formed CS from which migration 
was analyzed after 3 days (Fig. 4a). CS were stained for actin and DNA and the near complete overlap be-
tween actin and GFP staining demonstrates that these CS consist mainly of tumor cells. Next, cell suspen-
sions were derived by collagenase treatment of freshly isolated human osteosarcoma and chondrosarcoma 
tissue. Following injection, CS readily formed from these human biopsies and survival and migration could 
be studied for up to one week with the two tumor types showing distinct migratory behavior (Fig.4b). Osteo-
sarcoma mainly displayed individual amoeboid movement whereas chondrosarcoma showed predominantly 
individual mesenchymal movement. We treated these CS with the range of compounds described above at 
10 µM starting one day post-injection. Several of the chemical inhibitors effectively inhibited migration of 
both tumor types (Fig. 4b,c). Notably, the ROCK inhibitor Y-27632 did not affect mesenchymal movement but 
caused switching from amoeboid to mesenchymal movement in the osteosarcoma cells, in line with the de-
scribed requirement for ROCK activity only in amoeboid single cell movement (21). Taken together, these 
data indicate that the automated CS injection methodology has the potential to be used for drug testing on 
tumor cells freshly isolated from individual patients.
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FIGURE 4. Application to tumor biopsies. A, Overview DIC image (left) and zoom in on individual spheroid obtained from 4T1-GFP 
orthotopic mouse breast tumor. Scales, 1 mm (left DIC); 500µm (fluorescent images). B, DIC images showing spheroids derived from 
osteosarcoma (top) and chondrosarcoma biopsy (bottom) treated with indicated inhibitors. Scale, 100µm. C, effect of indicated inhibitors on 
CS migration over ~4 days determined from outline of migration strands derived for DIC images in A (mean and SD 12 spheroids derived 
from 2 wells is shown). D, Schematic overview of high-throughput spheroid screening indicating procedure at day 1 (steps 1-3) and imaging 
in absence or presence of compounds at days 2-8 (steps 4-6).
DISCUSSION
Here, we describe a method for generation of 3D CS cultures based on microinjection of cell suspensions 
into premade gels, that has a number of features making it highly useful for drug screening applications: 
compared to previous methods it is easy (one step procedure) and fast (minutes instead of days); CS are 
generated with high accuracy at predetermined x-y-z positions in multiwell plates; it is applicable to many 
different cell types irrespective of the ability of cells to form spontaneous cell-cell contacts; it shows good in-
tra- and inter-well reproducibility with respect to CS size and migration; because of the predefined coordi-
nates of each individual CS the method can easily be combined with fully  automated imaging and image 
analysis protocols (Fig. 5.4d). 2D culture conditions are a very poor representation of the environment cells 
encounter in vivo. Besides implications for cell biology studies, this has important consequences for the inter-
pretation of genetic - and drug screens (22). So far, these have mostly been performed on 2D cultures. For 
the study of tumor cell invasion the Boyden chamber assay (trans-well migration assay) is also commonly 
used. Here, a monolayer of cells migrates through a thin layer of gel to reach the bottom of a filter. This par-
ticular assay does not resemble cells disassociating from a solid tumor. For this purpose, CS cultures have 
been developed that provide a pathophysiological context that mimics solid cancer microenvironments. How-
ever, these have not been used for large-scale drug screens due to the complicated procedures, which nega-
tively affect reproducibility of results and lead to higher costs. Reproducibility of CS size is critical for a reli-
able 3D culture platform. Size and compactness of CS will inevitably affect drug penetration and previous 
studies have indicated that CS with diameters between 200 and 500µm are required to develop chemical 
gradients (e.g. of oxygen, nutrients, and catabolites) that may represent conditions found in tumors (3,4,23 - 
26). Our automated approach yields spheroids with a diameter of ~300µm, a size that may thus represents 
solid tumor traits.We have used collagen-based gels but the same method could be easily adapted to stud-
ies using alternative 3D matrices. The type and concentration of matrix proteins will have considerable influ-
ence on scaffold structure, rigidity, and porosity, which will impact on cell morphology, survival, proliferation, 
and migration efficiency (8,27,28). We find that changing collagen concentrations has a major impact on CS 
cell migration and that optimal conditions differ for distinct cell types, in agreement with findings from others 
(8,27-30). Hence, it is essential that gel formation is standardized and optimized for each cell type. The use 
of ECM proteins such as collagen has some limitation in terms of controlling batch-to batch variation. There-
fore, stabilization by chemical cross-linking may be applied to better control mechanical properties as poros-
ity and mechanical strength. A number of different cross-linking agents that react with specific amino acid 
residues on the collagen molecule, synthetic biopolymer scaffolds, and self-assembling synthetic oligopep-
tide gels are available to address this (27,28,31,32). We demonstrate that we can automate each step of the 
procedure, from injection of cell suspensions to imaging and image analysis, while maintaining reproducibil-
ity. Our method not only accelerates and simplifies CS formation but by generating up to 7 CS per well at 
predefined x-y-z coordinates it is compatible with fully automated imaging procedures, enhanced data collec-
tion, and robust statistical analysis. We present a small drug screen to demonstrate such properties. Finally, 
we show that the method presented here can be used for CS formation directly from freshly isolated tumor 
biopsy material without the need of any intermediate culture steps. This eliminates artificial traits induced by 
2D culture. A fully analyzed CS cancer migration screen in 96 well plates can be derived from a biopsy within 
1 week. This opens the door to screening on a patient-by-patient basis for drug sensitivity of tumor cells un-
der conditions that may closely mimic the in-vivo pathophysiological situation. Clinical tests to validate inhibi-
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tor effects in CS screens by comparing with therapeutic efficacy can be performed without further modifica-
tions of the presented system. Moreover, expansions of this method can be envisioned in which multiple cell 
types are combined (e.g. cancer cells and cancer-associated fibroblasts and/or endothelial cells) to further 
improve representation of the complex tumor microenvironment.
MATERIALS AND METHODS
Cell culture
The following cell lines were obtained from ATCC: MDA-MB-231, MTLn3, PC-3, HT1080, 4T1, and MAE. 
GEβ1 was described earlier(33). All cell lines were cultured under standard cell culture conditions indicated 
by ATCC or as described (33) at 37.C, 5% CO2 in a humidified incubator. Primary mouse tumor cell suspen-
sions were derived from surplus mouse breast tumor material by mincing using scalpel and tissue chopper 
followed by 2-hour collagenase treatment at 37 degree celsius. Human biopsy material was obtained from 
surplus material from patients that were surgically treated for chondrosarcoma or osteosarcoma. Tumor cell 
suspensions were derived from biopsies by 12h collagenase treatment at 37.C. All human specimens were 
handled in an anonymized coded fashion according to the National ethical guidelines for secondary use of 
patient-derived material.
Preparation of collagen
Collagen type I solution was obtained from Upstate-Milipore or isolated from rat-tail collagen by acid extrac-
tion as described previously (34). Collagen was diluted to indicated working concentrations of ~2.4 mg/mL in 
PBS containing 1xDMEM (stock 10x, Gibco), 44 mM NaHCO3 (stock 440 mM, Merck), 0.1 M Hepes (stock 
1M, BioSolve).
Hanging drop method
~ 5000 cells in 20 µL droplets were dispensed onto a 10 cm dish that was inverted over a dish containing 10 
mL DMEM. After 24h, cell aggregates were harvested using a Pasteur pipette and transferred into 10 cm 
dishes coated with 0.75% agarose submerged in 10mL DMEM. After 48h, spheroids had formed and these 
were embedded into a 2.4 mg/mL collagen solution using a Pasteur pipette. Collagen gels were allowed to 
solidify at 37.C for 30 min and overlaid with DMEM. Cell invasion was recorded for 3 days using an inverted 
phase contrast light microscope (Nikon Eclipse E600). 
Cell preparation for injection method 
Cell suspensions derived from trypsin-detached adherent cultures or from collagenase - treated biopsies 
were filtered to remove clumps, centrifuged at 1000 rpm for 5 minutes, and washed twice with PBS. ~7x106 
cells were re-suspended in 30 µL PBS containing 2% polyvinylpyrrolidone (PVP; Sigma-Aldrich). The PVP/ 
cell suspension was loaded into a beveled pulled glass needle (Eppendorf CustomTip Type III, OD [µm] 60, 
Front surface 40, Flexibility: rigid).
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Manual injection
Cell suspensions in 2% PVP were microinjected (~1x104 cells/droplet) with a microinjector (20 psi, PV820 
Pneumatic PicoPump, World Precision Instruments, Inc) into solidified collagen gels in 8 well µslides (IBIDI).
Automated injections
A glass-bottom 96 well plate (Greiner) containing 60 µL solidified 2.4 mg/ mL collagen gel per well was 
placed in a motorized stage (MTmot 200x100 MR, Marzhauser) connected to a controller (Tango, Marz-
hauser). A motorized micro-manipulator (Injectman II, Eppendorf) was positioned above the stage and con-
nected to a pump (Femtojet Express, Eppendorf) featuring an external compressor (lubricated compressor, 
model 3-4, JUN-AIR). A firewire camera (DFK41BF02.H, The Imaging Source) equipped with an 8x macro 
lens (MR8/O, The Imaging Source) was placed beneath the stage for calibration and imaging. All compo-
nents were connected to the controlling computer (Ubuntu AMD64). 
A multi-threaded control program was written in Python using PySerial and wxPython. Coriander software
(http://damien.douxchamps.net/ieee1394/coriander) was used for imaging.After the program was calibrated 
for the 96 well plate the camera height was adjusted to focus on the bottom of the 96 well plate. The plate 
was then removed for needle calibration: the injection needle was fixed in the Injectman and moved, using 
the  Injectman controller, into the center of the image. The injection height was set to 200µm above the bot-
tom of the (virtual) plate. After the needle was moved up, the plate was placed back in position and the up-
per left well was used for multiple test injections to adjust pump pressure and injection time for optimization 
of the droplet size (~8nL ~ 300µm diameter) using video inspection. Subsequently, using a pre-defined 
macro defining x-y coordinates and number of injections per well, all wells were injected with the same pres-
sure and injection time.
Microscopy and image analysis
Manually injected CS were monitored daily using a Nikon Eclipse E600 microscope. CS generated by auto-
mated injection were used for montage imaging using a Nikon TE2000 confocal microscope equipped with a 
Prior stage controlled by NIS Element Software and a temperature and CO2-controlled incubator. Differential 
interference contrast (DIC) images were captured using a charged coupled device (CCD) camera with NIS 
software at 10x dry objective. Quantification of CS invasion area was analyzed from DIC images using Im-
ageJ. The CS ellipsoidal area after three days was estimated using the diameter in x and y axis (pi*radius-
x*radius-y) occupied by cells in the 10x montage image in the mid-plane of each spheroid and normalizing to 
the occupied area 1h after injection. One-way ANOVA was performed to test the significance of the data. 
The data are presented and plotted as average and standard error of the mean. For automated imaging, 
wells containing gel-embedded spheroids were treated with a fixation and staining cocktail containing 3.7% 
paraformaldehyde, 0.2% Triton X-100 (Sigma) and 0.1 µM rhodamine Phalloidin (Sigma) for 3 hrs. Wells 
were washed extensively with PBS and plates were imaged on a Becton Dickinson Pathway 855 using a 4X 
lens. A montage of 12 frames was made for each Z plane, with a total of 24 Z planes at an interval of 50 µm. 
Image stacks were converted into 2D maximum fluorescence intensity projections using ImagePro 7.0. CS 
were then digitally segmented using ImageJ to identify the outline of individual CS and multiple parameters 
were measured, including Feret’s diameter, roundness, and number of CS scored in each well. For immu-
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nostaining of E-cadherin, gels were incubated for 30 mins with 5 µg/ mL collagenase (Clostridium histolyti-
cum, Boehringer Mannheim) at room temperature, fixed with 4% paraformaldehyde, permeabilized in 0.2% 
Triton X-100, and blocked with 10% FBS. Gels were incubated with E-cadherin antibody (BD Transduction 
Laboratories) overnight at 4 degree celsius followed by Alexa 488-conjugated secondary antibody (Molecu-
lar Probes/Invitrogen) for 2 hrs at room temperature and Hoechst 33258 nuclear staining (Molecular Probes/
Invitrogen) for 30 min at room temperature. Preparations were mounted in Aqua-Poly/Mount solution (Polys-
ciences, Inc) and analyzed using a Nikon TE2000 confocal microscope. Z-stacks (~100 stacks, step of 1 
µm) were obtained using a 20x dry objective, imported into ImageJ, and collapsed using extended depth of 
field plugin (Z projection) into a focused composite image.
Drug Treatment
LY-294002 (phosphatidylinositol 3-kinase), JSI-124-cucurbitacin (STAT3/Jak2), NSC23766 (Rac1), and AG-
82 (general protein tyrosine kinases) were purchased from Merck/CalBiochem. PP2 (Src) and ML-7 (MLC 
kinase) were purchased from ENZO. Y-27632 (Rock), SB-431542 (TGFβ) and AG1478 (EGFR) were pur-
chased from BioMol Tocris. Cell migration was analyzed in the absence and presence of inhibitors for 4 
days.
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AUTOMATED WHOLE ANIMAL BIO-IMAGING ASSAY 
FOR HUMAN CANCER DISSEMINATION
CHAPTER 3
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ABSTRACT
A quantitative bio-imaging platform is developed for analysis of human cancer dissemination in a short-term 
vertebrate xenotransplantation assay. Six days after implantation of cancer cells in zebrafish embryos, auto-
mated imaging in 96 well plates coupled to image analysis algorithms quantifies spreading throughout the 
host. Findings in this model correlate with behavior in long-term rodent xenograft models for panels of 
poorly- versus highly malignant cell lines derived from breast, colorectal, and prostate cancer. In addition, 
cancer cells with scattered mesenchymal characteristics show higher dissemination capacity than cell types 
with epithelial appearance. Moreover, RNA interference establishes the metastasis-suppressor role for E-
cadherin in this model. This automated quantitative whole animal bio-imaging assay can serve as a first-line 
in vivo screening step in the anti-cancer drug target discovery pipeline.
INTRODUCTION
Traditional anti-cancer drug screens are performed using cell lines grown in 2D culture or using in vitro pro-
tein binding assays. Cancer progression, however, is a complex process of dynamic interactions between 
cancer cells and the organism that involves genetic alterations leading to deregulated survival and prolifera-
tion, angiogenesis, invasion, and metastasis (1). Ideally, genes that play a role in this process are identified 
by in vivo ablation or silencing. Although genetic mouse models for cancer and human tumor cell xenotrans-
plantation models in rodents remain essential, such systems are costly, slow, and less amenable to high-
throughput assays for cancer drug target discovery. There is a clear need to develop fast, semi-automated 
in vivo systems for medium to high-throughput screening applications in preclinical target discovery and 
lead compound identification.
In this respect, zebrafish (ZF) offer a number of unique advantages for investigating the mechanisms that 
drive cancer formation and progression. ZF are vertebrates that can be raised in large numbers in a cost-
effective manner. An almost complete genome sequence reveals that most cancer genes and tumor sup-
pressor genes are highly conserved between ZF and humans, and ZF form spontaneous tumors with similar 
histopathological and gene expression profiles as human tumors (2-4). Importantly, xenotransplantation with 
human cancer cells is possible (5,6). ZF embryos that are used for this purpose lack an adaptive immune 
system, which increases the success of xenotransplantation while they provide a microenvironment where 
human tumor cells proliferate, migrate, form tumor masses, and stimulate angiogenesis (5-8). ZF embryos 
are particularly useful for semi high-throughput microscopic analysis platforms as they are translucent, and 
can be maintained in 96 well plates. The optical transparency of ZF offers exciting research opportunities 
allowing visualization of the metastatic process at high resolution (8,9). Recent findings indicate that a wide 
range of pharmaceutically active compounds illicit physiological responses in ZF embryos and inhibit dis-
ease development similar to effects in mammalian systems (10-12). These findings underscore the potential 
for a ZF embryo xenotransplantation model to be used in the anti-cancer drug discovery process. However, 
at this time, using ZF to screen for cancer relevant drug - and gene targets is limited by the lack of compre-
hensive automated bioassays. Here, we applied automated imaging and image analysis procedures to a ZF 
xenotransplantation model to develop the first semi-automated whole-organism quantitative bio-imaging as-
say for analyzing cancer dissemination in a vertebrate.
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RESULTS
We developed a noninvasive, quantitative whole animal bio-imaging method for dissemination of  xenotrans-
planted human cancer cells in ZF embryos in 96-well format. All the steps are briefly outlined in  Figure 1.
Automated image capturing and pre-processing
CMDiI-labeled tumor cells were injected in the yolk sac of 2-day-old fli-EGFP embryos (13) and fixed 6 days 
post-implantation (dpi) (Figure 1A). Fixed embryos were arrayed in 96 well glass bottom plates for auto-
mated imaging (<5 minutes per plate) (Figure 1B).  Epi-fluorescence microscopy failed to detect dissemi-
nated tumor cells due to excessive background from the primary tumor mass. Therefore, using a confocal 
laser-scanning microscope (CLSM) combined with an automated stage; multiple z stacks per embryo were 
captured for each well in a fully automated procedure (Figure 1C, 1D and Video S1). Confocal images were
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FIGURE 1. Schematic overview of the procedure. (A) Yolk sac implantation of CM-DiI labeled tumor cells into Tg (Fli:EGFP) ZF embryos 2 
days post-fertilization. (B) Formaldehyde fixed 6dpi embryos arrayed in 96 well plates. (C) Automated image acquisition using CLSM platform 
equipped with movable stage captures multiple Z stacks per embryo using 488 and 561 nm laser lines. (D and E) Automated creation of 
extended depth composite images. (F) Multiple extended depth images depicting embryos lying in different lateral orientations. (G) Automated 
uniform reorientation of images. (H) Scatter plot representing tumor foci burden in multiple embryos  belonging to one experimental condition.
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FIGURE 2. Outline of steps involved in embryo orientation. (A) Extended depth image of 6dpi ZF embryo. (B) Grey value image from 
combination of green and red channels. (C) Blurred grey image after applying closing filter to optimize determination of outline. (D) Embryo 
segmented after applying intensity threshold and area filter. Arrowhead indicates a red object outside the outline that is excluded from 
segmentation. (E) Cropped image with only selected object. (F) Embryo rotated by x° for horizontal reorientation. (G and H) Determination of 
the x position value of the center of mass (cm) and center of centroid (cc). (I) Horizontal flip of the image only if cm is on the left side of cc, 
resulting in images with the head of the embryo always to the right side. (J) Image after applying closed filter to the combined green and red 
channel to get the outline of the embryo. Point lying at 75% distance from the extreme left of the embryo outline is calculated. Y-axis is drawn 
at this X-position from upper to lower outline. Upper rectangle 1 is drawn. (K) Lower rectangle 2 is drawn. (L) Vertical flip of the image only if 
red intensity in rectangle 1 is higher than in rectangle 2. (M) Schematic representation of calculations for steps E-I. Altogether, this procedure 
results in images where the head is on the right and the yolk sac is on the bottom of the image. Scale bar = 200µm in E and I.
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FIGURE 3. Automated multiparametric quantification of PC3 tumor foci. (A) Extended depth image of 6dpi fixed embryo after realignment. (B) 
Embryo outline from segmented GFP channel and Y-axis intersecting X-axis at 75% from extreme left. (C) Calculated injection point at 75% 
distance from the extreme left and 75% from the top Y position. (D) Segmented red channel showing tumor foci burden in the embryo. (E) 
Identified tumor foci. (F) Multiple parameters of tumor foci burden calculated per embryo. Each number in the image corresponds to one tumor 
focus. (G) Tumor foci dissemination in a single embryo represented as scatter plot (coordinates 0,0 represents calculated injection site). (H) 
Combined scatter plot showing tumor foci dissemination from 39 injected embryos. (I) Quantification of cumulative distance (CD). Each filled 
square represents cumulative distance from injection point of all identified tumor foci in a single embryo. Mean cumulative distance (MCD) in 
the 39 injected embryos in this experiment is 15024 m. Scale bar = 200µm in A.
automatically converted into extended depth composite images (Figure 1E) that were rearranged to a uni-
form orientation (Figure 1F and G) to allow for automated quantitative image analysis (Figure 1H).
 
Automated multiparametric analysis of cancer cell dissemination
Having established conditions for automated imaging and image pre-processing of tumor cell implanted ZF 
embryos; we subsequently developed an algorithm for automated analysis of tumor foci burden in the post-
processed ZF images. For this, Image-Pro based software was developed, which performed essentially 
three major functions (see materials and methods section for detailed information on the macro’s). 1) Reori-
entation of the images (Figure 2): all embryos were automatically reoriented to a horizontal orientation, with 
the head towards the right and the yolk sac towards the bottom. 2) Determination of the injection position of 
labeled tumor cells (Figure 3A-C): the injection position was calculated from the images based on the seg-
mented GFP channel (and confirmed by visual inspection using the red channel). 3) Detection of tumor foci 
(Figure 3D and E): The red channel was segmented using an intensity threshold and minimum and maxi-
mum area filters. Data were exported to excel and multiple numerical parameters were calculated to de-
scribe the tumor cell burden per embryo. These included total number of tumor foci, average distance of tu-
mor foci from the injection site, and cumulative distance travelled from the injection site (Figure 3F). As only 
the cumulative distance parameter combined number of disseminated cells with their distance from the injec-
tion site, we reasoned that this parameter best reflected the tumor dissemination capacity (Figure S1). Data 
were represented as graphs displaying positions of tumor foci relative to the injection point (at coordinates 
x,y = 0,0) for each embryo (Figure 3G) or all embryos of a single experimental condition (Figure 3H). From 
these data, cumulative distance of all detected tumor foci was calculated per embryo (CD) and subse-
quently averaged for all injected embryos in one experimental group as a final quantitation of tumor cell dis-
semination (mean cumulative distance (MCD) (Figure 3I and S1). We performed experiments to determine 
the earliest time point that allowed robust discrimination between poorly aggressive and highly aggressive 
cell lines. Using LNCaP and PC3 as such an example for prostate cancer (14-19) we observed no differ-
ence at 2 dpi; MCD of PC3 could be distinguished from MCD of LNCaP at 4 dpi; and at 6 dpi MCD was 
markedly higher in PC3 compared to LNCaP with strong significance (Figure 4). Therefore, 6 dpi was cho-
sen for analysis in all further experiments.
To characterize tumor foci identified by this method, we calculated the mean diameter of segmented red ob-
jects in the tail region of PC3 implanted embryos. The average mean diameter was ~15µm with some larger 
objects up to ~45µm but no objects with average diameter <8µm being selected for the analysis, fitting with 
the identification of individual tumor cells or small clusters (Figure 5A). We further analyzed identified tumor 
foci by high-resolution imaging, 3D reconstruction, and surface rendering (Figure 5B and Video S2). This 
confirmed and extended the finding that single tumor cells or small clusters were identified by the automated 
image analysis and showed tumor cells interacting with the host vasculature (Figure 5B). To rule out arti-
facts due to CMDiI labeling, we injected mCherry labeled PC3 cells. In complete agreement with the proper-
ties of red objects identified after injection of CMDiI-labeled PC3, individual PC3-mCherry cells were ob-
served in close association with host blood vessels (Figure 5C and Video S3). Finally, experiments using 
unimplanted embryos (Figure 6A) and comparison of CM-DiI-labeled PC3 cells injected into standard fli-
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FIGURE 4. Determination of cancer cell dissemination kinetics. (A and B) LNCaP (A) or PC3 cells (B) were implanted and embryos were fixed 
at 2, 4, or 6 dpi for imaging (immunofluorescence images and automated image analysis (scatter plots). Bottom row images (scale bar = 50 
µm) show zoom-in of area marked by dotted line in top row images (scale bar = 100 µm). (C) CD at 2, 4 and 6 dpi for LNCaP (grey) and PC3-
injected embryos (black) calculated from scatterplots in A and B, respectively. Statistical testing for difference between LNCaP and PC3 at 
different dpi is indicated. *p<0.05, ***p<0.001.
47
FIGURE 5. Characterization of tumor cell foci identified by macro using high-resolution imaging. (A) Quantification of the mean diameter of 
macro-identified tumor cell foci from the tail region of PC3-injected embryos. Data obtained from 5 embryos. (B) High resolution imaging of 
CM-DiI-labeled PC3 tumor cell foci. (B1) Macro-identified PC3 tumor cell foci. (B2)  Zoom-in on area indicated in B1 shows tumor cells in asso-
ciation with host vasculature. (B3 and B4)  Three dimensional reconstruction and surface rendering of area in insert of B2; arrowheads point to 
tumor cell partly inside distal longitudinal anastomotic vessel (Video S2 and S3). (C) High resolution imaging of PC3-mCherry tumor cell foci. 
C1-4, as B1-4 for PC3-mCherry. Scale bar is 100 µm in B1 and C1; 50 µm in B2 and C2; 15 µm in B3 and C3; 10 µm in insets in B3 and C3; 5 
µm in B4 and C4.
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FIGURE 6. Excluding disturbance of the image analysis by autofluorescence signal from pigment cells. (A-C) In each case top left image 
shows green signal (Fli-EGFP) and top right image shows red signal for tumor cells. Bottom images show zooms of boxed area in top left 
image providing green (left) and red signal (middle) and transmitted light (right). Scale bar is 100 µm in images showing whole embryo and 
50 µm in zoomed images. (A) Non-implanted fli-EGFP embryo imaged at 8 days post fertilization. Number of non-implanted embryos and 
number of tumor cells (falsely) detected by automated imaging and image analysis method is indicated at the right. (B) Fli-EGFP embryo 
implanted with CM-DiI-labeled PC3 imaged at 6 dpi. (C) Fli-EGFP Casper embryo implanted with CM-DiI-labeled PC3 imaged at 6 dpi. 
EGFP or Casper fli-EGFP embryos lacking all pigments (Figure 6B and C), ruled out any false positives due 
to autofluorescence of pigment cells. Taken together, this method eliminates the need for visual scoring and 
enables automated generation and archiving of images and numerical data describing dissemination of tu-
mor cells in a vertebrate organism. Moreover, for tumor cells identified by this automated bio-imaging assay, 
tumor-host interactions can be further studied in detail by high-resolution microscopy.
Assay validation: correlation with behavior in mouse models and epithelial versus scattered 
phenotype
To demonstrate the applicability of our automated platform to differentiate between poorly aggressive and 
highly aggressive cancer cells, three different panels of cell lines were analyzed: 1) For prostate cancer, 
PC3 (highly metastatic in mouse models; prostate carcinoma / bone metastasis; androgen independent; 
scattered growth in 2D culture; mesenchymal markers) and LNCaP (very poorly metastatic in mouse mod-
els; prostate carcinoma / lymph node; expression of prostate differentiation markers; epithelial islands in 2D 
culture; epithelial markers) were analyzed (14-19). 2) For breast cancer, BT474 (metastatic in mouse mod-
els; breast invasive ductal carcinoma / duct; ER+/PR+/p53mutated; high Her2 expression; “weakly luminal 
epithelial like” phenotype in culture; reduced expression of epithelial markers) and MCF7 (very weak meta-
static potential in the absence of ectopically expressed oncogenes; breast adenocarcinoma / pleural effu-
sion; ER+/PR+/p53 normal; low Her2; epithelial islands in 2D culture; epithelial markers) were analyzed (20-
23). 3) For colorectal cancer, SW620 (colorectal adenocarcinoma Dukes’ type C / lymph node metastasis; 
scattered growth in 2D culture; mesenchymal markers) and HT29 (colorectal adenocarcinoma / colon; 
epithelial islands in 2D culture; epithelial markers) were analyzed (24). Strikingly, for each cancer type 
tested, dissemination in this ZF xenograft assay significantly correlated with metastatic capacity reported in 
mouse models and/or characteristics known to be associated with cancer progression including differentia-
tion markers or epithelial versus scattered phenotype (Figure 7A and B; Figure S2). These data validate this 
short-term automated bio-imaging method and show that it represents a powerful tool to predict aggressive-
ness of cancer cells in more complex, long-term in vivo systems.
Extensive ZF cellular movement takes place in the region of the yolk sac, where intestinal development oc-
curs within the time frame of our analysis (25). We wanted to exclude any influence of passive migration of 
implanted tumor cells due to this developmental process near the primary implantation area. For this rea-
son, we expanded the macro with an additional step in which all tumor foci within a square encompassing 
this region were excluded from the analysis in an unbiased automated fashion (Figure 7C and D). Although 
this may lead to underestimation of the cumulative distance parameter, we found that this exclusion step 
even further widened the window between the non-aggressive versus highly aggressive cell types (Figure 
7E). Moreover, analysis of several independent experiments using PC3, BT474, and MCF7, demonstrated 
that this methodology is highly reproducible (Figure 7F). We expanded the analysis to a broader panel of 
human cancer cell lines from different origins including prostate, breast, lung, colorectal, skin, and connec-
tive tissue. Interestingly, when these lines were grouped according to their morphology in 2D culture and ex-
pression of epithelial or mesenchymal markers, there was a clear correlation of high dissemination with a 
scattered phenotype (one notable exception was HT1299, which did not disseminate effectively); all cell 
lines growing as epithelial islands had very low dissemination capacity (Figure 8A; Table S1). We function-
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FIGURE 7. Differentiation between poorly and highly aggressive human cancer cell lines using automated bioimaging assay. (A) Scatter plot 
representation of tumor cell dissemination for indicated prostate (upper graphs), breast (middle), and colorectal cancer cell lines (lower graphs). 
Number of injected embryos from 2 biological replicates is indicated. (B) MCD determined from data represented in A. Data are presented as 
mean ± s.e.m. *p<0.05, ***p<0.001. (C) 6dpi embryo injected with PC3 showing tumor foci burden determined from segmented red channel 
(left), and represented as scatter plot (right). (D) Automated determination of region for exclusion of tumor foci around implantation site and in 
area of intestinal development (left), and remaining tumor foci represented as scatter plot (right).  (E) MCD before (black) and after exclusion 
(white bars) for the indicated prostate (left), breast (middle), and colorectal cancer lines (right graph). Fold difference between poorly and highly 
aggressive cell lines is indicated. Data are presented as mean ± s.e.m. *p<0.05, ***p<0.001. (F) MCD after exclusion for PC3 and MCF7 in 
multiple independent experiments demonstrates reproducibility. Data are presented as mean ± s.e.m.
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FIGURE 8. Differentiation between epithelial and mesenchymal cell types using the automated bioimaging assay. (A) MCD in a panel of 
human cancer cell lines from different origins. Number of injected embryos is indicated. White bars indicate cell lines showing a scattered 
phenotype in 2D cell culture. Black bars indicate cell lines growing as epithelial islands in 2D culture. Grey bars indicate cell lines with 
intermediate/mixed epithelial/mesenchymal characteristics. (B) 4T1 breast cancer cells growing as islands of loosely attached spindle-
shaped cells (left) and completely scattered growth of 4T1 cells following E-cadherin silencing (right). (C) E-cadherin surface expression by 
FACS. (D) Scatter plot representation of indicated 4T1 variants. Number of injected embryos from 2 independent experiments is shown. (E) 
Representative images of embryos injected with indicated 4T1 variants. (F) MCD determined from data represented in D. Data are 
presented relative to wild type 4T1 as mean ± s.e.m. **p<0.01. Scale bar is 200 µm in E.
- ally tested the role of one typical marker of the epithelial phenotype, the cell-cell adhesion receptor E-
cadherin. For this, we used 4T1 mouse breast carcinoma cells that possess an intermediate phenotype, 
growing as clusters of loosely attached cells in 2D and expressing E-cadherin as well as some mesenchy-
mal markers such as vimentin (Figure 8B). E-cadherin was silenced resulting in a fully scattered phenotype 
in 2D (Figure 8B and C) and these cells were injected in ZF to determine dissemination capacity. Indeed, 
shRNA targeting E-cadherin but not control shRNA strongly increased dissemination of 4T1 cells and the 
automated bio-imaging method allowed significant separation between 4T1shCdh1 on the one hand and 
4T1Wt and 4T1shCtr on the other (Figure 8D-F).
Altogether, a short–term medium throughput fully automated whole-organism bio-imaging model has been 
developed that distinguishes with good reproducibility cancer cell types that grow as islands or have epithe-
lial markers or have been shown to be poorly aggressive in mouse models from cell lines that are scattered 
or have more mesenchymal characteristics or are known to metastasize in mice. It is compatible with RNAi 
for identification of regulators of cancer cell dissemination and allows switching from low-resolution fast im-
aging to high-resolution detailed analysis to study effects on tumor cell properties or tumor cell-host interac-
tions.
DISCUSSION
Here, we developed a short term in vivo ZF xenograft assay that is compatible with automated imaging in 96 
well plates and coupled to fully automated analysis of tumor cell dissemination. This assay represents the 
first automated whole organism bioimaging assay in a vertebrate that allows for studying aspects of cancer 
progression. Our findings show that this assay closely reflects the results obtained in more expensive and 
much lower throughput assays such as rodent xenografts. The ZF xenograft model has been previously ap-
plied to cancer migration studies (5-9). There are limitations to this model, including potential differences in 
the host microenvironment and the need to work at temperatures that are compatible with survival and mi-
gration of mammalian cells while at the same time being favorable for normal ZF physiology. Nevertheless, 
we have modified experimental conditions such that behavior of a large panel of human cancer cell lines 
from various origins closely resembles known behavior in rodent models. Moreover, our work provides this 
model with the automation in imaging and image analysis as well as with the statistical power required for 
application in screening procedures. We provide proof-of-principle for such applicability by testing a known 
regulator of cancer cell migration. Using a panel of cell lines we show that this imaging platform can discrimi-
nate between cell types with more epithelial characteristics or growing in islands versus those with more 
mesenchymal characteristics or displaying a scattered phenotype. We then combine the assay with RNAi to 
silence the cell-cell adhesion molecule, E-cadherin. We rapidly obtain data from ~90 animals per experimen-
tal group in two biological replicates supporting the inhibitory role of E-cadherin in cancer dissemination.
Taken together, this relatively fast medium throughput assay may be used as a first in vivo analysis platform 
in the target discovery pipeline. It provides the automation and statistical power to identify those hits from 
large-scale in vitro RNAi screening efforts that warrant more time- and money-consuming studies in mouse 
models. Future directions will include incorporation of similarly automated analysis of induction of tumor angi-
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ogenesis and tumor cell proliferation to capture multiple aspects of cancer progression within this bio-
imaging assay.
MATERIALS AND METHODS
Cell lines and ZF handling
All human cancer cell lines were obtained from ATCC and cultured according to the provided protocol. ZF 
and embryos were raised, staged and maintained according to standard procedures in compliance with the 
local animal welfare regulations. The transgenic ZF line Tg (fli1:EGFP) expressing EGFP in endothelial cells 
in wild type or “Casper” background, was maintained according to standard protocols (http://ZFIN.org). PC3-
mCherry cells were generated using a pCMV-mCherry-bc-puro-Kl201 lentiviral vector (provided by Dr. R.C. 
Hoeben, Leiden University Medical Center, Leiden NL). 4T1-shCdh1 and 4T1-shCtr cells were generated by 
lentiviral transduction using TRC shRNA constructs (Sigma).
Implantation procedure
Mammalian cells were labeled with lipophilic fluorescent cell tracker (CM-DiI; excitation maximum 553 nm, 
lot no. C7000; Invitrogen) according to the manufacturers instructions. The labeled cell suspension was 
loaded into borosilicate glass capillary needles (1mm O.D. x 0.78mm I.D.; Harvard Apparatus) and the intray-
olk injections were performed using a Pneumatic Pico pump and a manipulator (WPI). Dechorionated 2 
days post-fertilization ZF embryos were anesthetized with 0.003% tricaine (Sigma) and positioned on a 
10cm petridish coated with 1% agarose. By controlling injection pressure and duration the number of in-
jected cells was set at ~100 per embryo as determined by standard cell counting of injection droplets. In-
jected embryos were maintained in egg water at 34°C and fixed 6 dpi with 4% paraformaldehyde.
Automated microscopy and high-resolution imaging
Fixed embryos were manually arrayed into 96 well glass bottom plates (material no.655892; Greiner) with 
each well containing a single embryo. This was easily done in <5 min per plate. Image acquisition was per-
formed by using a Nikon Eclipse Ti CLSM, which integrates advanced optics, fluorescence detection and 
scanning hardware in a single platform controlled by EZ C1 software. 488 and 561 nm laser lights were 
used to excite Tg (fli1: EGFP) embryos and DiI- positive tumor cells. Serial sagittal (lateral) sections were 
captured 6 dpi in an automated fashion (14 x 30 µm) using a Plan Apo 4X Nikon dry objective with 0.2 NA 
and 20 WD. For three dimensional images 0.5 µm step Z stacks (1024x1024 focal planes, 50-74 µm in 
depth) were acquired by using 40x Nikon dry plan fluor objective with 0.75 N.A and 0.66 WD.
Image analysis software
Automated image pre-processing, automated analysis, and 3D reconstruction and surface rendering were 
performed by Image-Pro Plus-based software from Media Cybernetics.
Extended depth of field
The software used Z-stack color images from the confocal microscope. The obtained gray images were 
pseudo colored with green for GFP and red for CM-DiI labeled tumor cells. A macro was built that uses both 
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channels for batch processing of all images in a folder. First from the Z-stack a single, in-focus, composite 
image was made. Pixels in the Z-stack were analyzed. For every position, the pixel from the plane with the 
largest variance or local contrast was selected. This pixel was then used for the final composite image.
Automated orientation of the embryos (Figure 2)
For the image analysis, all embryos should have the same orientation. For this, a macro was developed in 
which the images were modified so that all embryos were horizontally oriented, with the head towards the 
right and the yolk sac towards the bottom of the image.
- Automated horizontal alignment: The color image was converted to a grey value image to give a combina-
tion of the GFP and red channels. The embryo was then segmented using mean intensity histogram value 
and minimum and maximum area filter. Then, a direction value of the segmented object was determined, 
which was used to give the embryo a horizontal position.
- Automated horizontal orientation: The X position value of the center of mass was determined from the grey 
combined GFP and red channels. If this value was located left from the center of centroid, the image was 
flipped horizontally. In all cases, this provided images in which the head of the embryo was oriented to the 
right.
- Automated vertical orientation: From the outer horizontal positions, the point lying on the X-axis at 75% dis-
tance from the extreme left of the embryo outline was determined. At this X-position the Y-axis was drawn 
from top to bottom outlines. A rectangle was drawn from -20 to +20 pixels horizontally from the calculated 
75% point and vertically 80 pixels above the middle of the upper Y-axis. Another rectangle was drawn with 
identical horizontal parameters and vertically 80 pixels below the middle of the lower Y-axis. The average 
fluorescence intensity in the red channel was determined for both rectangles. If intensity was higher in the 
upper rectangle compared to the lower rectangle, the image was flipped vertically. The same procedure 
could be performed using the GFP channel in which case images were flipped if intensity was higher in the 
bottom rectangle. Visual inspection showed that this procedure, in all cases resulted in images where the 
yolk sac was oriented to the bottom of the image.
-  Automated calculation of the injection position of the Cy3 labeled cells:
First the leftmost and the rightmost X positions of the embryo outline were determined. From these X posi-
tions, a point lying at 75% from the extreme left was determined. Then, from this X position the uppermost 
and lowermost Y positions were determined. Subsequently, from these Y positions a point lying at 75% from 
the uppermost Y position was determined, which was designated as the arbitrary injection point. Visual in-
spection showed that the arbitrary injection point by this procedure, always resided within the primary tumor 
mass.
Automated detection of CMDil labeled tumor cells
The pseudo colored red objects were segmented using a threshold value, and by applying a minimum and 
maximum area filter. After the segmentation, a mild watershed separation was applied. For all detected red 
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objects the distance (in µm) from the injection point was calculated. A positive X value indicates tumor foci 
towards the head; a positive Y value indicates tumor foci towards the dorsal region of the embryo. Various 
other parameters, including number of objects, mean distance, cumulative distance, mean area, and mean 
intensity were calculated for segmented red objects.
Processing of the results in excel
All data, together with the image were exported into excel. In excel 2 macro’s were used:
a) Exclusion of tumor foci where [X absolute] is within 500 µm and [Y absolute] is within 200 µm from the 
calculated injection point; b) Calculation of the average of all analyzed embryos. The major calculation cho-
sen for representation of the data was “mean cumulative distance” (MCD) of tumor foci from injection posi-
tion.
Statistical analysis
Statistical analysis was performed with Prism 4 software (GraphPad) using two tailed, unpaired t-test. ns, 
not significant; *, P<0.05; **, P<0.01; ***, P<0.0001.
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ABSTRACT
Radiotherapy is one of the treatment options for locally or regionally advanced prostate cancer, but radiore-
sistance of prostate cancer cells is a practical limitation of radiotherapy. The identification of molecular tar-
gets of radioresistance in prostate cancer is important to improve therapeutic intervention. The aim of this 
review is to give more biological insight into some well known processes involved in radioresistance of pros-
tate cancer especially Apoptotic pathway; DNA damage response; and NF-kB signaling pathway. This review 
integrates salient, published, research findings with underlying molecular mechanisms, preclinical efficacy, 
and potential clinical applications of combining radiotherapy with these molecular targeted agents for the 
treatment of prostate cancer.
INTRODUCTION
The standard treatment regimen for clinically localized disease in prostate cancer is either radical prostatec-
tomy or radiation therapy through external beam irradiation or local radioactive seed implants (brachyther-
apy) (1). A major reason for failure to eradicate local disease in prostate cancer and other solid tumors by 
radiotherapy (RT) is the radioresistance (2). Generally, there are two types of radioresistance in solid tu-
mors: External mediated by interactions with microenvironment (Cell-cell and cell-matrix interactions (3) and 
local paracrine signaling), and internal (mediated by the general survival pathways like mutated p53) (4), am-
plification of DNA repair genes, overexpression of anti-apoptotic genes, increased levels of reactive oxygen 
species scavengers, activation of prosurvival/poor prognosis oncogenes such as Epidermal growth factor 
receptor (EGFR) (5,6) or c-MET(also known as hepatocyte growth factor receptor) (7,8). Molecular targeting 
of these survival mechanisms is now becoming a reality with new treatments designed to target processes 
that are thought to be tumor specific, or where there are quantitative differences in target expression be-
tween cancer and normal cells. The relative tumor-specificity of most molecular targeted agents may offer a 
theoretical advantage over chemotherapy, as overlapping toxicity with RT on normal tissue is potentially mini-
mized. Furthermore, the intrinsic radiosensitivity of certain tumors may be modified by agents that target spe-
cific gene and protein expression. An illustrative example of this advantage is the targeting of EGFR expres-
sion to reduce proliferation of head and neck cancer cells without affecting the repopulation of normal muco-
sal epithelial cells required for healing during radiotherapy (9-11). This fundamental information has, in turn, 
suggested that targeting such radio response regulatory molecules can serve as a strategy for developing 
radiation sensitizers.
OVERCOMING RADIORESISTANCE IN PROSTATE CANCER BY 
TARGETING APOPTOSIS
Irradiation-induced tumor apoptosis can be enhanced by targeting of apoptotic machinery that involves a sys-
tem of messengers.The challenge of apoptosis-targeting, as in all therapies, is to selectively target pathways 
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FIGURE 1.Schematic model showing the activation of different pathways leading to apoptosis in the prostate cancer cell lines (LNCaP/PC3). 
Pro-apoptotic signaling is activated via upregulation of p53, release of ceramide (e.g., by sphingomyelinase (SMase) due to XRT or by vari-
ous cytokines like TNF- alpha. Ceramide is metabolized by a ceramidase to generate sphingosine. Sphingosine is phosphorylated by sphin-
gosine kinase to form Sphingosine-1-Phosphate (S-1P). S-1P antagonizes ceramide-mediated apoptosis. All signals are integrated at the 
level of mitochondria by activation or upregulation of pro-apoptotic molecules belonging to the pro-apoptotic Bcl-2 family (Bax, Bak, Puma, 
Noxa). The relative level of pro and anti-apoptotic Bcl-2 molecules is the key decision point regarding cell death induction. In case of relative 
overweight of pro-apoptotic Bcl-2 members, cytochrome c is released from mitochondria and triggers execution of apoptosis by activation of 
caspase-9 and secondary caspases that cleave intracellular substrates, thereby inducing the apoptotic phenotype, including nuclear chroma-
tin condensation and fragmentation. XIAP and survivin which belongs to the class of IAP (Inhibitor of apoptosis) proteins, inhibit the activation 
of the caspase cascade leading to the radioresistance. 
Abbreviations: Smase: sphingomyelinase; SM: sphingomyelin; CS: ceramide synthase; C: Cytokine; CR: Cytokine Receptor; DMS: N,N-
Dimethyl sphingosine 1. Smase 2. Ceramidase 3. sphingosine kinase; 4.Sphingosine N-methyl transferase
By Targeting Sphingomyelin-Ceramide Pathways
Radiation targets either the cell membrane or the nucleus to activate different apoptotic pathways (12-14). 
Sphingomyelin-Ceramide apoptotic pathway (Fig. 1) is initiated by hydrolysis of sphingomyelin through acti-
vated sphingomyelin-specific forms of phospholipase C, termed sphingomyelinases (SMases) that leads to 
generation of ceramide (12-14). Ceramide, in turn, can activate several pathways important for the induction 
of apoptosis (14). Also, Ceramide is further metabolized by ceramidase to generate sphingosine (Fig. 1), 
which in turn, can be phosphorylated by sphingosine kinase (Sphk) to form Sphingosine-1-phosphate (S-1P) 
(15,16). Conversely, S-1P has been implicated as a signaling molecule that antagonizes ceramide-mediated 
apoptosis (17). The modulation of ceramidase, sphingosine kinase, and S-1P phosphatase activities play a 
pivotal role in the regulation of apoptosis by regulating the intracellular ratio between ceramide, sphingosine, 
and S- 1P (17). Furthermore, Sphk1/S1P pathway has been linked to oncogenic transformation and cancer 
progression via increased rate of cell proliferation, and apoptotic resistance (18-20). Sphk1 is highly ex-
pressed in various human tumor tissues (21,22) and has been shown to be associated with poor prognosis 
in gastric cancer (23), glioma (24) and breast cancer (25). Radioresistance of Prostate cancer has been re-
ported to be linked to sustained sphingokinase- 1(Sphk-1) activity (26). Recently, a new sphingosine ana-
logue FTY720 (Finglimod) has been shown to induce radiosensitization and inhibition of tumor growth in in 
vitro and in vivo models (27).
Various in vitro studies (outlined in Table 1) have shown that the Sphingomyelin-Ceramide pathway is a very 
attractive target for radio-sensitization in prostate cancer. After critically analyzing all these in vitro studies it 
can be hypothesized that ceramide generation is a critical component of radiation-induced apoptosis in hu-
man prostate cancer cells and blockage of ceramide generation may provide a selective advantage in the 
development of radioresistance of prostate tumors. Because of the central role of Sphingomyelin-Ceramide 
pathway in radiation induced apoptosis, pharmacologic manipulation of the intracellular ceramide levels in 
conjunction with radiation could offer significant improvement to the clinical treatment of prostate cancer.
By Targeting Anti-apoptotic Bcl-2 Family of Proteins
Antiapoptotic Bcl-2 (B-cell lymphoma 2) protein is overexpressed in a variety of human cancers, including 
prostate cancer (28,29). Bcl-2 overexpression is frequently found in both primary and metastatic human pros-
tate cancers (30,31). It is observed to be overexpressed in 30% to 60% of prostate cancer at diagnosis and 
in nearly 100% of hormone-refractory prostate cancers (31). Also, Bcl-xL (B-cell lymphoma-extra large) is 
found to be overexpressed in 80% to 100% of hormone-refractory prostate cancers, where it is associated 
with bad prognosis, shortened survival and advanced disease (32). Bcl-2/Bcl-xL overexpression decreases 
the pro-apoptotic response to such cellular insults as irradiation, chemotherapy, and androgen withdrawal, 
leading to resistance to treatment (33). Primary prostate tumors overexpressing Bcl-2 exhibit a high Gleason 
score and a high rate of cancer recurrence after radical prostatectomy (30,31). The most definitive evidence 
supporting a positive correlation between Bcl-2 and prostate cancer progression is that Bcl-2 overexpression 
leads to metastatic and chemo- or radioresistant phenotypes (34,35). Reversal of prostate cancer cell ra-
dioresistance in vitro has been achieved by downregulating Bcl-2 (36,37). Bcl-2 and Bcl-xL represent an at-
tractive target for the development of new anti-prostate cancer agents that have either direct cytotoxic ef-
fects on prostate cancer cells or improve the efficacy of conventional radio- or chemotherapy by sensitizing 
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prostate cancer cells (Fig. 1). Various in vitro studies as shown in (Table 1) provide firm evidence, that target-
ing antiapoptotic Bcl-2 family of proteins represents an attractive target for prostate cancer  radiosensitiza-
tion.
Targeting the IAP (Inhibitor of Apoptosis) Member of  Proteins
IAPs represent a class of apoptosis regulatory proteins consisting  of eight family members: Neuronal apop-
tosis inhibitory protein (NAIP; also known as BIRC1), cellular IAP1 (c-IAP1; also known as BIRC2), cellular 
IAP2  (c-IAP2; also known as BIRC3), X chromosome-linked IAP (XIAP; also known as BIRC4), survivin 
(BIRC5), ubiquitin-conjugating BIR domain enzyme apollon (also known as BIRC6), melanoma IAP (ML-IAP; 
also known as BIRC7),  and IAP-like protein 2 (ILP2; also known as BIRC8) (38,39). Among all human IAP 
proteins, XIAP and survivin have been reported to have the most prominent and strongest antiapoptotic func-
tion (40,41). IAPs function as potent endogenous apoptosis inhibitor (Fig. 1) due to their ability to bind and 
effectively inhibit two effector caspases (-3 and -7) and one initiator caspase-9 (42). A notable exception is-
survivin which only inhibits active caspase 9 after binding to its cofactor hepatitis B-X-interacting protein 
(HBXIP) (43). Additionally, it has been shown that anti-apoptotic action of survivin could be mediated by its 
interaction with XIAP leading to increased stability of XIAP (44). IAPs suppress apoptosis against a variety of 
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TABLE 1. Shows preclinical studies, which demonstrate the potential of targeting Sphingomyelin-Ceramide pathway, Bcl-2 antiapoptotic  and 
IAP family of proteins for prostate cancer radio-sensitization.




TNF- alpha + irradiation LNCaP Intracellular ceramide levels    Enhanced activation of the 
intrinsic mitochondrial 
 apoptosis pathway. 
Sphingosine  and   SPP levels. 
          115 
Exogenous C2 ceramide+ 
irradiation 
LNCaP Intracellular ceramide levels    enhanced activation of the 
intrinsic mitochondrial  
                  apoptosis pathway 
          116 
Exogenous sphingosine + 
irradiation 
LNCaP Sphingosine levels    enhanced apoptosis of the        
radiation resistant prostate cancer cells. 
          26 
Sphingosine kinase 
inhibitor (N,N-DMS) + 
Irradiation. 
LNCaP Sphingosine levels    enhanced apoptosis of the   
radiation resistant prostate cancer cells. 
          26 
TPA +irrradiation LNCaP  Ceramide synthase activity    ceramide levels  
   (in- Vivo pathway)     enhanced apoptosis 




(-)Gossypol+ irrradiation - PC-3 
- PC-3 xenograft 
Blocks heterodimerization of Bcl-xL with Bax, Bad and Bim    
 enhanced response to 
 radiation therapy. 





Reduction in Bcl-2 protein levels and a significant   reduction in 
clonogenic survival. 
      117 
HA14 -1+ irrradiation -PC-3 
-LNcaP 
HA14 –1 is an organic Bcl-2 inhibitor   enhanced  
response to radiation. 
     118 
Curcumin+ irrradiation PC-3 Downregulation of endogenous and radiation Induced Bcl-2 
protein expression    enhanced   radiation induced 
apoptosis. 
      37 
TARGETING 
IAP MEMBER OF 
PROTEINS 
Smac mimetic SH-130 DU-145 Functional blocking of IAPs     enhanced radiation 
induced apoptosis. 
      53 
Embelin PC-3 Inhibits XIAP   enhanced radiation induced apoptosis            54 
apoptotic stimuli, which include radiation, chemotherapy and immunotherapy in cancer cells (38). Specifi-
cally, radiation triggers release of mitochondrial proteins (Smac, cytochrome-c and survivin) into the cyto-
plasm (41,45). Consequently the released Smac binds to XIAP and other IAP proteins, thus abolishing their 
anti-apoptotic function (45). It has been shown that IAPs are highly expressed in many types of cancer in-
cluding prostate cancer (39,42,46,47). Expression of cIAP1, cIAP2, XIAP, survivin, and NAIP has been exam-
ined in the NCI -60 human tumor cell line panel, which revealed widespread expression of cIAP1, XIAP, and 
survivin in tumor lines of diverse tissue origins (48). Genome wide analysis has confirmed the differential ex-
pression of survivin in tumors versus normal tissues (49). Survivin has been shown to be overexpressed in 
prostate cancer cell lines, aggressive prostate cancers with higher gleason grades, lymph node and distant 
metastasis (50-52). Because IAPs suppress apoptosis against a variety of apoptotic stimuli, including radia-
tion, strategies targeting IAPs may prove to be highly effective in overcoming radiation resistance (Fig. 1). 
Against this background a number of different strategies have been developed to antagonize aberrant IAP 
protein function and/or expression in human prostate cancers as to overcome radioresistance (53,54). Some 
of these strategies are briefly outlined in the (Table 1).
TARGETING DNA DAMAGE RESPONSE PATHWAYS
Ionizing radiation (IR) leads to the formation of DNA single or double-strand breaks, altered or lost DNA 
bases and DNA-DNA or DNA protein cross-links (55). The DNA-damage response pathway begins with ‘sen-
sor’ proteins that sense the DNA damage and/or chromatin alterations that occur after induction of DNA dam-
age (56). These ‘sensor’ proteins convey the damage signal to transducers which in turn transmit it to numer-
ous downstream effectors(56). The DNA-double strand breaks (dsbs) are first recognized by the (Telomere 
binding protein) TRF2 and Mre11– Rad50– Nbs1 (MRN) sensor complex. The MRN sensor complex is the 
most important sensor complex (Fig. 2) comprising the nuclease Mre11, the structural maintenance of chro-
mosomes protein Rad50 and the protein Nbs1 (57,58). The transducers consist of a group of conserved nu-
clear protein kinases (59) and the ‘phosphatidylinositol-3-OH kinase (PI (3) K)-related protein kinases’ 
(PIKKs), which consists further of the DNA-dependent protein kinase (DNA-PK), ataxia-telangiectasia-
mutated (ATM), the ATM and Rad3-related (ATR) protein and hSMG-1 (60,61). Current evidence suggest 
that the MRE11–RAD50–NBS1 complex (MRN complex) is the primary DSB sensor that recruits ATM to the 
DNA-dsbs (62). Another early step in the response to a DSB involves phosphorylation of the H2A histone 
family, member X, H2AX, which is redundantly carried out by ATM or DNA-dependent protein kinase (DNA-
PK)(63). Phosphorylation of H2AFX produces discrete, microscopically detectable foci (64). The MRE-11 
and H2AFX proteins further recruit DNA repair complexes and cell cycle checkpoint proteins (e.g. tumor pro-
tein 53 binding protein 1 (TP53BP1), mediator of DNA damage checkpoint 1 (MDC1), breast cancer 1, early 
onset (BRCA1), and check point kinase 2 (CHK2) (65). After initial sensing and activation of downstream 
pathways, parallel activation of human DNA-double strand break repair pathways homologous recombina-
tion (HR) and non-homologous recombination takes place, which can both interact or compete with each 
other during cell cycle transitions (66).
Cell cycle checkpoints or DNA repair pathways are commonly altered during the process of prostate cancer 
(66). Tumors having these genetic alterations are hypothetically sensitive to radiation upon further disruption 
of remaining checkpoint functions or remaining DNA repair pathways. The most important DNA-dsb damage
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FIGURE 2. Showing schematic outline of DNA damage response pathway and possible therapeutic strategies for radiosensitization in the pros-
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expression + RT(119). 
siRNA mediated attenuation  
of DNA-PKcs + RT(127). 
1.PARP inhibitors:3-AB,ISQ,NU1025, 
  KU0058684 (121). 
 
2.siRNA mediated attenuation of RAD51(127). 
 
3.Ribozyme minigene mediated RAD51 
   downregulation + RT(127). 
-response genes associated with prostate cancer risk includes the ATM-p53 signalling axis, such as ATM, 
p53, and CHK2 (67). It has been shown that ATM expression is higher in the high gleason score prostate 
tumors, when compared to the normal tissues (68). Prostate cancer specimens have been shown to harbor 
p53 mutations that have been documented to be associated with androgen independence, metastasis, de-
creased disease free survival and radioresistance (59,69). Keeping this background in mind, ATM has been 
targeted in prostate cancer using specific antisense or siRNA approaches resulting in radiosensitization 
(70).Small molecular inhibitors or peptides have been generated to bind to mutant forms of p53 and revert-
ing them to wild type conformation and leading to cell cycle arrest and apoptosis (69). Malignant prostate 
cancer cell lines express higher levels of RAD51, XRCC3, RAD52 and RAD54 genes involved in homolo-
gous recombination in comparison to normal prostate epithelial cells (71). Strategies that target DNA repair 
increase radiosensitization in vitro and in vivo after treating prostate, glioma and lung cancer cells with 
siRNA to RAD51 (72,73). Prostate cancer arising in BRCA2 mutation carriers display an aggressive tumor 
phenotype and present more poorly differentiated tumors when compared with non-carrier prostate cancer 
controls (74-76). It has been shown that cells defective in BRCA1 and BRCA-2 proteins exhibit reduced 
RAD51 activity and foci formation and show increased sensitivity to ionizing radiation (77,78). Furthermore, 
It has been observed that BRCA1 and BRCA2 deficiency sensitizes cells to the inhibition of Poly (ADP-
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TABLE 2. Showing various pre-clinical studies which have showed the potential of targeting DNA damage response pathway for prostate cancer 
radiosensitization.
TARGET  AGENT USED    MODEL USED            MECHANISM        REF. 
ATM – P53 –
MDM2 
PATHWAY 
Adenoviral mediated P53gene 
expression + XRT 
-P53 defficient PC3 line 
-P53 wild type LNCAP 
cell line 
Restoration/enhancement of normal 
p53 function Enhancement of 
apoptosis. 
 119 
Antisense MDM2+AD+XRT P53 wild type LNCAP cell 
line 
- MDM2 expression and P53 and 
p21 expression. 
- Apoptosis and clonogenic 
survival. 
120 
siRNA mediated attenuation of the 
ATM, ATR expression 
 + XRT 
- DU 145 
- PC-3 
Post-transfection levels of the ATM, 





Genetically engineered PARP 
mutant, expressing dominant 
negative mutant of PARP in tumor 
cells+ XRT 
Tumor xenograft - PARP is required for the efficient 
repair of DNA singlestrand breaks 
(SSBs) during base excision repair  
and PARP inhibition leads to 
persistent singlestrand gaps in 
DNAthese gaps are encountered by 
a replication fork, leading to arrest, 
and the single-strand gaps may 
degenerate into DSBs. 
 
- In the absence of BRCA1 or BRCA2, 
the replication fork cannot be restarted 
and collapse , causing persistent 
chromatid breaks  Repair of these 
breaks by alternative error prone DSB 
repair mechanisms would cause large 
numbers of chromatid breaks and 
aberrations, leading to loss of viability. 
    121-126 
siRNA /antisense /Ribozyme 
minigene mediate attenuation of 
RAD51 
LNCaP      Downregulation of RAD 51      127 
Ribose) Polymerase (PARP) enzymatic activity, which consequently leads to chromosomal instability, cell 
cycle arrest and apoptosis (79). PARP-1 (accounting for 80% of total PARP cellular activity) binds to both 
single and double strand DNA breaks and is involved in DNA single strand break (ssb) repair and break exci-
sion repair (80,81). It has been documented that inhibition of PARP increases the level of unrepaired DNA 
double strand breaks by a variety of mechanisms.Based on these principles, Ashworth and colleagues 
adopted an siRNA approach and observed an increased sensitivity to PARP inhibition in a variety of cells 
which were made deficient in proteins in HR or Fanconi’s anemia pathway (like RAD51, RAD54, DSS1, 
RPA1, NBS1, ATR, ATM, CHK1, CHK2, FANCD2, FANCA or FANCC) (83). Targeting cancer cells harboring 
a specific DNA repair defect by inhibiting a second repair pathway is a representation of synergistic lethality 
(84), and this approach is rapidly being translated into effective treatments for hereditary BRCA1 or BRCA2 
deficient cancers or with tumors harboring defects in HR repair pathways (85). Utilizing this principle, spe-
cific and potent inhibitors of PARP inhibitors (Fig. 2) have been developed that are very effective tumor radio-
sensitizers in in-vitro and in-vivo (84). 
The various preclinical studies which have demonstrated the potential of targeting these pathways for pros-
tate cancer radiosensitization are outlined in (Table 2). These studies support the concept that the predeter-
mination of the repair capacity of tumor cells may help to select appropriate agents for use in combination 
with radiotherapy in prostate cancer.
BY TARGETING RADIATION INDUCED RADIOADAPTIVE NF- kB 
PATHWAY
Radio-adaptive response is assumed to be induced by activation of the specific prosurvival signaling net-
work in irradiated mammalian cells leading to reduced cell sensitivity to a subsequent higher challenging 
dose when a smaller inducing radiation dose had been already applied (86). The earliest response of mam-
malian cells to ionizing irradiation consists of activation of transcription factors, like AP-1, p53 (also known as 
TP53), and NF-kB (87,88). Out of all these, NF-kB has served as a model system for inducible transcription 
in a broad range of physiological and medical effects. The mammalian NF-kB family of proteins consists of 
five members: RelA, RelB, c-Rel, p50 (NF-kB1) and p52 (NF-kB2) (89). All members of the NF-kB family pos-
ses a Rel-homology domain (RHD) containing a NLS (nuclear localization sequence), which is important for 
dimerization, DNA binding and its interaction with IkB proteins (most important inhibitors of NF-kB activa-
tion). In the majority of circumstances NF-kB is found in the cytoplasm where it is negatively regulated by its 
interaction with the IkB family of proteins. These IkB family of proteins possesses multiple ankyrin repeats 
which bind to the RHD and masks NLS of NF-kB (90). There are various stimuli that activate NF-kB, which 
results in the regulation of a myriad NF-kB target genes. The majority of proteins encoded by NF-kB target 
genes participate in the host immune response (91,92), cell adhesion and stress response (91), apoptosis 
regulators (93), growth factors (94), cell cycle regulators (95) and inflammatory cytokines (96).In cancer 
cells, it regulates the expression of many anti-apoptotic proteins (IAP1, IAP2, XIAP,cFLIP and BclxL). It also 
regulates the progression of the cell cycle by positively regulating the expresson of various cyclins (D1,D2, 
D3, and E) and c-myc (97). NF-kB is also known to stimulate invasion and angiogenesis by regulating the 
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expression of different matrix metalloproteinases (MMP-2, MMP-9) (98) and various angiogenic factors (IL-8 
and VEGF) (94,96).
Moreover, the activation of NF-kB is considered to be the most important factor, involved in the inflammatory 
response generated by irradiation (99,100). It has been shown that increased basal NF- kB activity in certain 
cancers has been associated with tumor resistance to radiation and chemotherapy (101). NF-kB is activated 
after phosphorylation of IkB at two serine residues (Ser-32 and Ser-36) by IkB kinases, which is later polyu-
biquitinated, and then degraded by 26S proteasome (Fig. 3). The free NF-kB translocates to the nucleus and 
activates its target genetic programs (102) including manganese superoxide dismutase (MnSOD), an en-
zyme that catalyses the conversions of toxic superoxide radicals to hydrogen peroxide and molecular oxy-
gen (103-105). The radioadaptive response mediated by the NF-kB members increases the expression of 
MnSOD leading to protection of tumor cells (106,107). NF-kB also modulates the apoptotic signals at vari-
ous levels. The best example is found in the TNF receptor I signaling pathway (108). (Fig. 3) provides the 
schematic representation of NF-kB signaling network in radiation induced adaptive radioresistance in pros-
tate cancer. 
Numerous studies have demonstrated the importance of the NF- kB pathway and its role as a cause of ra-
dioresistance in prostate cancer cell lines:
a). Josson and colleagues demonstrated that, constitutive nuclear level of RelB are significantly higher in 
PC-3 compared to LNCaP cells. They also showed that PC3 cells have a higher basal levels of MnSOD as 
compared to the LNCaP cells. These results suggest that comparatively higher levels of nuclear RelB and 
MnSOD protein may be responsible for the intrinsic radiation resistance of PC-3 cells (109). Selective inhibi-
tion of RelB decreased the levels of MnSOD leading to increase in the sensitivity of prostate cancer cells to 
radiation treatment (109). Xu and colleagues showed that interaction of 1-alpha, 25-dihydroxyvitamin D3 (1al-
pha, 25-(OH) 2D3) with the Vitamin D receptor (VDR) enhanced the radiosensitivity of prostate cancer cell 
lines at clinically relevant radiation doses. The radiosensitization effect of 1-alpha, 25-(OH)2D3 is partly medi-
ated by selectively suppressing IR-mediated RelB activation, leading to decreased expression of manga-
nese superoxide dismutase (MnSOD), suggesting that suppression of MnSOD is a mechanism by which 1-
alpha, 25-(OH) 2D3 exerts its radiosensitization effect. Therefore,   1-alpha, 25-(OH) 2D3 is a high potential 
effective pharmacologic agent for selectively sensitizing prostate carcinoma cells to irradiation via suppres-
sion of antioxidant responses in mitochondria (110). Yulan Sun and colleagues showed that inhibition of NF-
kB pathway is also a common mechanism for the radiosensitization effect of parthenolide in prostate cancer 
cells LNCaP, DU145, and PC3 (111). Radiation-induced NF-kappaB DNA-binding activity is inhibited by par-
thenolide leading to the decreased transcription of the sod2 gene, the gene coding for an important antiapop-
totic and antioxidant enzyme (manganese superoxide dismutase) in the three prostate cancer cell lines 
(111). Using immunohistochemical studies, Lessard and colleagues demonstrated that all the members of 
the NF-kB family were expressed in normal prostate tissues, prostatic intraepithelial neoplasia and prostate 
cancer. However, only the nuclear localization of RelB correlated with the prostate cancer patient’s Gleason 
scores (112), suggesting that the level of RelB is associated with prostate cancer progression. These studies 
provide us convincing evidence that RelB plays an important role in redox regulation of the cell and protects 
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aggressive prostate cancer cells against radiation-induced cell death. Thus, inhibition of RelB could be a 
novel mechanism to radiosensitize prostate cancer.
b). Damodaran and colleagues demonstrated using p53 deficient PC3 cell line, that radiation also causes an 
induction of TNF- alpha protein expression, NF-kB activity and Bcl-2 upregulation (37). They also showed 
that radiation-induced NF-kB activity depends on radiation induced expression of TNF-alpha. Curcumin in 
combination with programs (102) including manganese superoxide dismutase (MnSOD), an enzyme that ca-
talyses the conversions of toxic superoxide radicals to hydrogen peroxide and molecular oxygen (103-105). 
The radioadaptive response mediated by the NF-kB members increases the expression of MnSOD leading 
to protection of tumor cells (106,107). NF-kB also modulates the apoptotic signals at various levels. The best 
example is found in the TNF receptor I signaling pathway (108). (Fig. 3) provides the schematic representa-
tion of NF-kB signaling network in radiation induced adaptive radioresistance in prostate cancer. 
Numerous studies have demonstrated the importance of the NF- kB pathway and its role as a cause of ra-
dioresistance in prostate cancer cell lines:
a). Josson and colleagues demonstrated that, constitutive nuclear level of RelB are significantly higher in 
PC-3 compared to LNCaP cells. They also showed that PC3 cells have a higher basal levels of MnSOD as 
compared to the LNCaP cells. These results suggest that comparatively higher levels of nuclear RelB and 
MnSOD protein may be responsible for the intrinsic radiation resistance of PC-3 cells [109]. Selective inhibi-
tion of RelB decreased the levels of MnSOD leading to increase in the sensitivity of prostate cancer cells to 
radiation treatment [109]. Xu and colleagues showed that interaction of 1- alpha, 25-dihydroxyvitamin D3 (1 
alpha, 25-(OH) 2D3) with the Vitamin D 
receptor (VDR) enhanced the radiosensitivity of Prostate Cancer cell lines at clinically relevant radiation 
doses. The
radiosensitization effect of 1-alpha ,25-(OH)2D3 is partly mediated by selectively suppressing IR-mediated 
RelB activation, leading to decreased expression of manganese superoxide dismutase (MnSOD), suggest-
ing that suppression of MnSOD is a mechanism by which 1-alpha , 25-(OH) 2D3 exerts its radiosensitization 
effect. Therefore, 1-alpha, 25-(OH) 2D3 is a high potential effective pharmacologic agent for selectively sen-
sitizing prostate carcinoma cells to irradiation via suppression of antioxidant responses in mitochondria 
[110]. Yulan Sun and colleagues
showed that inhibition of NF-kB pathway is also a common mechanism for the radiosensitization effect of 
parthenolide in prostate cancer cells LNCaP, DU145, and PC3 [111]. Radiation-induced NF-kappa B DNA-
binding activity is inhibited by parthenolide leading to the decreased transcription of the sod2 gene, the gene 
coding for an important antiapoptotic and antioxidant enzyme (manganese superoxide dismutase) in the 
three prostate cancer cell lines [111]. Using immunohistochemical studies, Lessard and colleagues demon-
strated that all the members of the NF-kB family were expressed in normal prostate tissues, prostatic intra-
epithelial neoplasia and prostate cancer. However, only the nuclear localization of RelB correlated with the 
prostate cancer patient’s Gleason scores [112], suggesting that the level of RelB is associated with prostate 
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FIGURE 3. Schematic presentation of the NF-kB signaling network in radiation-induced adaptive radioresistance in prostate cancer. 1. Radia-
tion induces TNF-alpha ligand expression. Binding of TNF-alpha to its receptor, leading to recruitment of adaptor proteins (AD). 2/3. Activation of 
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Abbreviations: RT = Radiotherapy; ROS=Reactive Oxygen Species
aggressive prostate cancer cells against radiation-induced cell death. Thus, inhibition of RelB could be a 
novel mechanism to radiosensitize prostate cancer.
b). Damodaran and colleagues demonstrated using p53 deficient PC-3 cell line, that radiation also causes 
an induction of TNF- alpha protein expression, NF-kB activity and Bcl-2 upregulation (37). They also showed 
that radiation-induced NF-kB activity depends on radiation induced expression of TNF-alpha. Curcumin in 
combination with radiation caused inhibition of TNF- alpha - mediated NF-kB activity resulting in downregula-
tion of bcl-2 protein leading to the enhanced radiation-induced clonogenic inhibition and radiation-induced 
apoptosis in p53 deficient PC-3 cells (113). Curcumin inhibits NF-kB activation by inhibiting phosphorylation 
of IkB-alpha, which is required to export NF-kB from cytosol to nucleus as to activate its target genes (113). 
Together, these mechanisms strongly suggest that the natural compound Curcumin is a potent radiosensi-
tizer, and that it acts by overcoming the effects of radiation-induced prosurvival gene expression in prostate 
cancer.
c). Julian and colleagues showed that Genistein (4', 5,7 trihydroxyisoflavone) combined with radiation 
causes greater inhibition in PC-3 colony formation compared to genistein or radiation alone due to the strong 
inhibition of the NF-kB activity (113). Their findings support the novel strategy of combining genistein with 
radiation for the treatment of prostate cancer. All these studies demonstrate the role of NF-kB as a stress 
factor in prostate cancer cells. NF-kB is a crucial element of the cell’s protective response to radiation and 
represents therefore an attractive target in new therapeutic approaches to fight prostate cancer. Inhibition of 
NF-kB is expected to increase the therapeutic efficiency of radiation.
CONCLUSIONS AND REMAINING QUESTIONS
The identification of molecular targets of radioresistance in prostate cancer cells is very important to improve 
therapeutic intervention in prostate cancer. Anyhow, an ideal molecular targeting agent should improve the 
therapeutic efficacy of radiotherapy by targeting specific pathway(s), in practice, but this may be difficult to 
achieve with predictability because of the complex molecular cross-talk between signaling pathways (113). 
The most challenging part for a clinical investigator is to interpret this large amount of preclinical data and, 
then to select the most promising molecular targeting agent suitable for human clinical trials. Moreover, there 
are other challenges that are faced during the designing of the early clinical trials for molecular targeted 
agents. It is unknown whether expression of the molecular target can adequately predict clinical response to 
molecular agents (55). There are also several issues in studying radiosensitizers at the molecular level using 
prostate cancer cell lines, including their heterogeneity, different growth properties, hormone responsive-
ness, originated from metastatic tissue,etc. Nevertheless, these cellular models have provided considerable 
understanding of the biology of prostate cancer and are important for the initial investigation process. Moreo-
ver, our current knowledge of radiation-induced pathways is incomplete, and it does not provide direct proof 
for improving the efficacy of radiation therapy. In this context, the advent of RNA interference technology 
(114) can provide us a better insight into the radiation induced biomolecular pathways by virtue of its high 
selectivity for molecular targets. Functional genomic studies utilizing siRNA high throughput libraries can pro-
duce unbiased information regarding the molecules involved in the prostate cancer radioresistance. This ge-
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nome wide approach will reveal new molecules involved in prostate cancer radioresistance, and it will lead 
to the development of new molecular targeted radiosensitizing strategies in prostate cancer.
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ABSTRACT
In an adenoviral RNAi screen using a zebrafish xenograft automated bioimaging platform (1), we identify 
SYK as a kinase supporting human prostate cancer dissemination. SYK has not been previously implicated 
in prostate cancer and we confirm SYK mRNA and protein expression in human prostate cancer specimens. 
Stable lentiviral silencing confirms a role for SYK in zebrafish xenografts and demonstrates that SYK sup-
ports in vitro invasive outgrowth of prostate cancer spheroids. In a mouse experimental prostate cancer me-
tastasis model, SYK RNAi prevents bone colonization and this effect is reversed by wild type but not kinase 
dead SYK expression. In absence of SYK, cell surface expression of the progression-associated adhesion 
receptors, integrin alpha-2 and CD44 is diminished and silencing alpha-2 phenocopies SYK depletion in vitro 
and in vivo. Finally, pharmacological inactivation of SYK similarly interferes with invasive growth and dissemi-
nation. As SYK inhibitors are already in Phase I-II clinical trials for rheumatoid arthritis and lymphoid malig-
nancies (2, 3), these preclinical findings can be immediately translated to the clinic to assess efficacy in the 
treatment of prostate cancer.
INTRODUCTION
Prostate cancer is the most common cancer in males and the second leading cause of cancer deaths 
among men in the Western world (4). Non-detectable micro-metastatic disease may be present in up to 40% 
of patients (5) while 8–14% may have visible or symptomatic bone metastases at diagnosis (6). Although the 
majority of prostate cancers are diagnosed as organ-confined disease, which is curable by prostatectomy or 
radiation therapy, 20-25% of patients will experience relapse within 5 years of treatment (7). Once the dis-
ease has spread beyond the prostate, no curative treatments are currently available (8). In addition to 
screening programs for early diagnosis and treatment of localized disease, there is an urgent need for novel 
targeted therapies to improve treatment of metastatic prostate cancer.
RESULTS AND DISCUSSION
A panel of prostate cancer cell lines was xenografted in the yolk of zebrafish and dissemination was ana-
lyzed using a whole animal automated bioimaging platform as described (1). Prostate cancer cell lines re-
ported to be androgen-independent and/or metastatic in mice (LNCaP-derived C4-2 and C4-2B; DU145 and 
PC3) showed enhanced dissemination in comparison with androgen-dependent non-metastatic cells 
(LNCaP) (9-12) (Fig S1). We therefore devised an adenovirus-based RNAi screen for mediators of prostate 
cancer dissemination using this platform (Fig 1a). Two independent shRNAs targeting the protein tyrosine 
kinase, SYK were identified that significantly inhibited PC3 spreading in two independent experiments using 
~25 embryos per condition (Fig 1b,c; Fig S2). Additional genes fulfilling these criteria included the cell sur-
face hyaluronan receptor, CD44 and the tyrosine kinase, Src (Fig 1b) that have already been linked to 
growth and progression of prostate cancer (13-16).
SYK has been extensively implicated in lymphoid malignancies (3) and appears to play opposing roles in 
different solid tumors (17, 18) but has not been previously associated with prostate cancer. Two independent 
lentiviral SYK shRNAs confirmed the role of SYK in dissemination in the zebrafish xenograft model (Fig 1d; 
Fig S3). SYK RNAi also appeared to reduce outgrowth of cells at the primary injection site (Fig S2) and 
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See next page for figure legend 
Figure 1
c 
where cell spheroids are embedded in three dimensional (3D) extracellular matrix (ECM) scaffolds (19), si-
lencing SYK attenuated spheroid expansion and effectively blocked ECM invasion (Fig 1f; Fig S4; Video S1). 
No signs of increased nuclear fragmentation in SYK-depleted spheroids were observed, pointing to de-
creased proliferation rather than cell death as the underlying mechanism (Fig S4).
We next analyzed SYK expression in human prostate cancer. Compared to LNCaP, mRNA expression was 
increased in the androgen-independent LNCaP-derived C4-2 and C4-2B sublines and in DU145 and PC3 
androgen-independent, metastatic prostate cancer cell lines (Fig 1g). Likewise, in a series of human pros-
tate cancer xenografts (20), SYK mRNA expression was higher in androgen-independent tumors (Fig 1h) 
and SYK expression in prostate cancer metastasis resection specimens was significantly increased com-
pared to primary prostate cancer in two datasets (Fig 1i). Since the stromal compartment may affect mRNA 
analysis in clinical samples, SYK protein expression was analyzed in a set of primary prostate cancer speci-
mens. Immunohistochemistry validated SYK expression in prostate cancer cells and expression was in-
creased in prostate cancer versus normal prostate epithelium (Fig 1j).
In acute lymphoid leukemia (AML), inhibition of SYK promotes differentiation (21). We analyzed a set of tran-
scripts previously associated with undifferentiated characteristics of prostate cancer cells (22) but observed 
no gross changes in the expression of these genes upon depletion of SYK. However, while mRNA levels of 
the prostate cancer progression-associated markers CD44 and integrin α2β1 (13, 14, 23-25) were unaf-
fected (Fig S5); their cell surface expression was lost following SYK depletion (Fig 2a). SYK has been previ-
ously reported to regulate surface expression of transmembrane receptors (26, 27) and two adenoviral 
CD44 shRNAs were identified as hits in our primary screen (Fig 1b). Moreover, lentiviral silencing of α2 or 
β1 integrin subunits, each by two independent shRNAs, suppressed 3D ECM invasion as well as dissemina-
tion in the zebrafish model (Fig 2b,c; Fig S6). A role for  β1 integrins in intravascular locomotion of tumor 
cells in zebrafish has been previously reported (28). Together, these results identify regulation of surface ex-
pression of adhesion receptors as a potential underlying mechanism for the support of prostate cancer dis-
semination by SYK.
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FIGURE 1. SYK is expressed in human prostate cancer and supports growth, invasion, and dissemination of prostate cancer cells. (a) 
Schematic overview of the in-vivo screening procedure. (b) Mean cumulative distance (MCD) of tumor foci relative to site of injection for PC3 
cells transiently transduced with indicated adenoviral shRNAs calculated from >40 xenografts obtained from two independent experiments. (c) 
Representative scatter plots showing tumor foci detected by automated confocal imaging and automated image analysis as described (1) in 
zebrafish injected with PC3 cells expressing indicated adenoviral shRNAs. Each color shows foci detected in one embryo. Arrows indicate foci 
in tail region. (d) MCD and representative images for dissemination in zebrafish of PC3 cells stably expressing indicated lentiviral SYK shRNAs 
(combined data from 2 independent experiments using >32 embryos per condition are shown). (e) Quantification of colony formation assay for 
PC3 cells expressing indicated lentiviral SYK shRNAs. Grey, small; white, medium; black, large colonies. (f) Representative images and 
quantification of expansion (mean spheroid area) and ECM invasion (MCD) for control and shSYK PC3 cell spheroids 6 days post-injection in 
collagen gels (blue, Hoechst; red, Phalloidin). Scale bars, 100 µm. (g) SYK RNA expression determined by qPCR in indicated cell lines. MDA-
MB-435S (hypermethylated SYK gene promoter (35, 36)) and HCC-1954 breast cancer cells (high SYK expression (36)) were used as negative 
and positive controls, respectively. (h) SYK RNA expression in human prostate cancer resection specimens xenografted in mice. (i) Ratio 
between SYK RNA expression in prostate cancer metastases (MetPCa) and primary prostate cancers (PCa) and significance (TTEST) in two 
different datasets. (j) Immunohistochemical staining of SYK protein in three different prostate cancer specimens (1-3). Arrows point to 
cytoplasmic staining in cancer cells. Arrowheads in enlargement 3’ point to infrequently observed nuclear staining. ns, not significant; *p<0.05; 
** p<0.01; ***p<0.005.
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Figure 2.See next page for figure legend
We next addressed the role of SYK in a preclinical mouse xenograft model for prostate cancer bone metasta-
sis (29). Depletion of SYK led to a strong reduction in metastatic tumor burden following intracardiac inocula-
tion of PC3M-Pro4luc cells (Fig 2d,e). Similar to its effect in vitro and in zebrafish xenografts; shRNA target-
ing integrin 2-subunit mRNA, phenocopied shSYK in this model (Fig 2d). To further interrogate the specific 
role for SYK kinase activity in prostate cancer bone colonization, wild type or kinase dead SYK was ex-
pressed in PC3M-Pro4luc cells expressing an shRNA targeting the SYK 3’UTR. Wild type but not kinase 
dead SYK rescued the in vitro colony forming ability of these cells (Fig 2f). Moreover, effective bone coloniza-
tion of shSYK cells was restored by wild type SYK while expression of kinase dead SYK even further sup-
pressed the process with very few detectable metastases (Fig 2g-i).
Based on these findings, we performed initial experiments to evaluate whether pharmacological inhibition of 
SYK could interfere with in vitro invasive outgrowth and in vivo dissemination using zebrafish xenografts. 
Small molecule inhibitors of SYK are in clinical development for autoimmune diseases and lymphoid malig-
nancies (2, 3). Two of these compounds, R-406 and BAY-61-3606 show efficacy in preclinical leukemia and 
retinoblastoma studies (21, 30-33). When used at 1-10µM, the concentration widely used in vitro (21, 30-33) 
these compounds reduced spheroid outgrowth and ECM invasion of PC3 as well as C4-2B cells (Fig 3a-c). 
Moreover, R-406 significantly inhibited dissemination of PC3 cells (Fig 3d) without significant signs of toxicity 
at 10µM (e.g. yolk sac edema, cardiac edema, bending of the tail, hepatic necrosis, and impaired cardiovas-
cular function were compared for R-406 and vehicle control treated animals). Thus, pharmacological inactiva-
tion of SYK using R-406 and BAY-61-3606 recapitulated the effect of silencing the SYK gene in vitro and in 
zebrafish xenografts.
In summary, we demonstrate that a semi-automated whole animal bioimaging assay based on zebrafish xe-
notransplantation (1) can be productive in RNAi-based preclinical target discovery and lead compound identi-
fication. We show that genetic and pharmacological inactivation points to a role for SYK in invasive growth 
and dissemination of prostate cancer. SYK mRNA and protein is detected in human prostate cancer tissues 
and SYK inhibitors have already been tested in phase I-II clinical trials for other diseases. Altogether, this 
establishes SYK as a potential new drug target in prostate cancer for which existing pharmacological inhibi-
tors with known toxicological profiles can be tested for clinical efficacy.
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FIGURE 2. SYK regulation of adhesion receptor surface expression in human prostate cancer cells modulates dissemination in zebrafish and 
metastatic colonization in mice. (a) FACS analysis of surface expression of CD44 and integrin subunits α2(ITGA2) and β1(ITGB1) in PC3 cells 
expressing indicated SYK shRNAs. MFI, mean fluorescence intensity. (b,c) Representative images (b) and quantified MCD (c) for dissemination 
in zebrafish of PC3 cells expressing indicated lentiviral shRNAs (combined data from 2 independent experiments using > 40 embryo’s per 
condition are shown; Scale bar is 100 µm). Arrow heads indicate tumor foci in tail region. (d) Total metastatic tumor burden determined by BLI 
monitoring at indicated time points following intra-cardiac inoculation in immune-compromised mice for PC3M-Pro4luc variants expressing 
indicated lentiviral shRNAs (data obtained from at least 9 mice per experimental group). (e) Bones of mice collected 31 days after intracardiac 
inoculation with PC3M-Pro4-luc shCTR or shSYK cells and stained with Goldner staining. *, tumor lesion. (f) Quantification of colony formation 
assay for PC3M-Pro4-luc cells expressing control or SYK shRNAs in combination with wild type (SYKwt) or kinase dead SYK (SYKkd) 
expression vectors. Grey, small; white, medium; black, large colonies. (g) BLI images of PC3M-Pro4luc variants expressing control or SYK 
shRNAs in combination with wild type (SYKwt) or kinase dead (SYKkd) expression vectors taken 31 days following intra-cardiac inoculation. 
(h,i) Quantification of the experiment shown in (g) where total metastatic tumor burden was determined by BLI monitoring at indicated time 
points (h) and the number of metastatic colonies was determined by counting of BLI foci at 31 days following intra-cardiac inoculation (data 






























































R-406:1µM R-406:10µM vehicle 
FIGURE 3. Pharmacological inhibition of SYK prevents growth, invasion, and dissemination of prostate cancer cells. (a) 
Bright field images showing PC3 spheroids 6 days post-injection into collagen gels in the absence or presence of the 
indicated concentrations of BAY-61-360 (one of three experiments is shown). (b) Representative images and quantification 
of expansion (mean spheroid area) and ECM invasion (MCD) for PC3 cell spheroids measured at 6 days post-injection in 
collagen gels and treated with indicated concentrations of R-406 (blue, Hoechst; red, Phalloidin; scale bar is 120 µm). (c) 
Brightfield images showing C4-2B cell spheroids at 6 days post formation in the absence or presence of the indicated 
concentrations of SYK inhibitors. Arrowheads point to ECM invading strands seen under control conditions, which are not 
observed in presence of inhibitors. Scale bar is 120 µm. (d) Representative images and quantified MCD for dissemination in 
zebrafish of PC3 cells in the absence or presence of indicated concentrations of R-406. Combined data from 2 independent 
experiments using >70 embryos per condition are shown. Arrows point to cells disseminated to tail region. Scale bar is 
100µm; ns, not significant; *p<0.05; ** p<0.01; ***p<0.005.
METHODS
See supplemental information for detailed Materials and Methods.
LNCaP, PC3 and DU-145 cells were obtained from ATCC and cultured according to the provided protocol. 
PC3M-Pro4luc cells have been described previously (29). LNCaP-derived cell lines C4-2 and C4-2 B were 
grown in T-Medium. Zebrafish embryo xenografting followed by automated confocal imaging and image 
analysis algorithms were previously described (1). Dissemination is described as cumulative distance from 
injection site of tumor cells in each embryo averaged over all embryos (mean cumulative distance; MCD). 
For the shRNA screen, PC3 cells were transduced with adenoviral shRNA constructs 5 days prior to xeno-
transplantation. Stable PC3 and PC3M-Pro4-luc cell lines were generated by lentiviral shRNA (TRC; Sigma) 
transduction followed by bulk puromycin selection. Wild type or kinase dead (K402R) SYK retrovirus (34) (a 
kind gift from Drs. Wei Zou and Steven Teitelbaum, Washington University, St Louis MO) was transduced in 
PC3M-Pro4-luc cells stably expressing shRNA targeting the SYK 3’UTR, followed by bulk blasticydin selec-
tion. RNA isolation, qPCR, immunohistochemistry on paraffin-embedded tissues, and FACS were done us-
ing standard protocols. Growth and ECM invasion was studied for cell spheroids embedded in collagen gels 
as described (19) and quantified using an automated Image pro 7-based plugin to calculate surface area of 
spheroid, number of cells migrating out and cumulative distance travelled by these cells. The latter is de-
scribed as MCD. Experimental bone metastasis in mice was analyzed by weekly whole body bioluminescent 
imaging (BLI) and Goldner bone staining in nude mice following intracardiac injection with PC3M-Pro4luc 
cells as described (29). Data for all experiments are presented as mean ± SEM of at least 3 independent bio-
logical replicates unless otherwise stated. Student's t test (two-tailed) was used to compare groups.
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SUPPLEMENTARY INFORMATION : METHODS 
Cell lines and antibodies
LNCaP, PC3 and DU-145 cells were obtained from ATCC and cultured according to the provided protocol. 
PC3-M-Pro4luc cells have been described previously (1). LNCaP-derived cell lines C4-2 and C4-2B were 
grown in T-Medium. For FACS, primary antibodies included AIIB2 anti-human integrin β1, 4A10 anti human 
integrin α2, and sc-18849 anti-human CD44 (Santa-Cruz). Goat-anti-mouse APC and donkey-anti-rat PE 
(Jackson laboratories) were used as secondary antibodies. For immunohistochemistry in patient tumor sam-
ples Syk N-19 Ab (sc-1077; Santa Cruz) was used. 
Zebrafish xenotransplantation experiments
For quantification of tumor cell spreading, tumor cells were labeled with CM--DiI (Invitrogen), mixed with 2% 
PVP, and injected into the yolk sac of enzymatically dechorionated, two-day old Casper fli-EGFP transgenic 
zebrafish embryos using an air driven microinjector (20 psi, PV820 Pneumatic PicoPump; World precision 
Inc). Embryos were maintained in egg water at 34°C for 6 days and subsequently fixed with 4% paraformal-
dehyde. Imaging was done in 96 well plates containing a single embryo per well using a Nikon Eclipse Ti 
confocal laser-scanning microscope. Z stacks (12 x 30 µm) were obtained using a Plan Apo 4X Nikon dry 
objective with 0.2 NA and 20 WD. Images were converted into a single Z projection in Image-Pro Plus (Ver-
sion 6.2; Media Cybernetics). Automated quantification of cumulative tumor cell spreading per embryo was 
carried out using an in-house built Image-Pro Plus plugin as previously described (2). 
Transient adenoviral shRNA transduction
PC3 cells were transduced one day after seeding with adenoviral shRNA constructs from Galapagos BV (Lei-
den, the Netherlands) using an MOI of 15 for 24 h. After 3 days, medium was replaced and after an addi-
tional two days, the transduced PC3 cells were detached with trypsin and single cell suspensions were used 
for zebrafish xenotransplantation. 
Stable shRNA and cDNA expression
PC3 or PC3-M-Pro4luc cells were transduced using Sigma’s MISSION library lentiviral shRNAs (shSYK#1: 
T R C N 0 0 0 0 0 0 3 1 6 7 , s h S Y K # 2 : T R C N 0 0 0 0 1 9 9 5 6 6 ; s h I T G B 1 # 1 : T R C N 0 0 0 0 0 2 9 6 4 5 , 
shITGB1#2:TRCN0000029646; shITGA2#1: TRCN0000057730, shITGA2#2: TRCN00000057731).  For len-
tivirus production, HEK293T cells were transfected with the short hairpin constructs together with the packag-
ing plasmids REV, GAG and VSV in a 1:1:1:1 ratio using PE (Sigma) as transfection reagent. Lentiviral su-
pernatant was collected 48 h after transfection and used for transduction or target cells in the presence of 8 
µg Polybrene (Sigma). Transduced cells were bulk selected in medium containing 2 µg/ml puromycin.  Len-
tiviral shRNA vector targeting TurboGFP was used as a negative control. Retroviral cDNAs for wild type and 
kinase dead SYK were a gift from Drs. Wei Zou and Steven Teitelbaum, Washington University, St Louis MO 
(3). Retrovirus was produced in Plat-E packaging cells and used for transduction of PC3-M-Pro4-luc cells 
stably expressing shRNA targeting SYK 3’UTR, followed by bulk blasticidin selection. 
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mRNA expression analysis
For qPCR, total RNA was extracted using RNA easy Plus Mini Kit (Qiagen). cDNA was randomly primed 
from 50 ng total RNA using iScript cDNA synthesis kit (BioRad) and real-time qPCR was subsequently per-
formed in triplicate using SYBR green PCR (Applied Biosystems) on a 7900HT fast real-time PCR system 
(Applied Biosystems). 
The following qPCR primer sets were used: 
GAPDH: forward AGCCACATCGCTCAGACACC,       reverse ACCCGTTGACTCCGACCTT;  
SYK forward GATGCTGGTTATGGAGATG,                 reverse TCTATGATGTTCTTATCCTTGAC; 
CD44 forward TGGCACCCGCTATGTCCAG,              reverse GTAGCAGGGATTCTGTCTG; 
ITGB1 forward ATTGACCTCTACTACCTT,                  reverse GTGTTGTGCTAATGTAAG;  
ITGA2 forward AACTCTTTGGATTTGCGTGTG,         reverse TGGCAGTCTCAGAATAGGCTTC.  
Data were collected and analyzed using SDS2.3 software (Applied Biosystems). Relative mRNA levels after 
correction for GAPDH control mRNA, were expressed using 2^(-∆∆Ct) method. For mRNA expression analy-
sis of human prostate cancer patient material either directly or following xenografting in mice, existing data-
sets were queried as described (4). 
Colony-Forming Assay
Cells were seeded into a 96-well plate containing ~1 cell per well. After 1 to 3 weeks, percentage of wells 
showing colonies and colony size was determined by microscopy (Zeiss Axiovert 200M). 
3D invasion assays
Cell suspensions in PBS containing 2% polyvinylpyrrolidone (PVP; Sigma-Aldrich) were microinjected 
(~1x104 cells/droplet) using an air driven microinjector (20 psi, PV820 Pneumatic PicoPump; World preci-
sion Inc) into solidified 3D collagen gels in 8 well µslides (IBIDI) as previously described (5). Collagen gels 
were prepared from 2.5 mg/ml acid-extracted rat tail collagen type 1. Collagen was diluted to working con-
centration of 1 mg/ml in complete medium containing 44 mM NaHCO3 (stock 440 mM, Merck) and 0.1 M 
Hepes (stock 1M, BioSolve).  Tumor cell spheroids were monitored for ~1 week using Nikon eclipse TS100. 
For immunostaining, gels were incubated for 1 hour with 5 µg/ml collagenase (Clostridium histolyticum, Boe-
hringer Mannheim) at room temperature, fixed with 4% paraformaldehyde, and permeabilized in 0.2% Triton 
X-100. After fixation, collagen gels were stained using a cocktail containing 4 % paraformaldehyde, 0.2% Tri-
ton X-100 (Sigma) and 0.1 µM rhodamine Phalloidin (Sigma) for 3 hrs. Thereafter, wells were washed with 
PBS. Preparations were then mounted in Aqua-Poly/Mount solution (Polysciences, Inc) and imaged using a 
Plan Apo 4X Nikon dry objective with 0.2 NA and 20 WD. A total of 15 Z planes at an interval of 30 µm were 
captured. Image stacks were converted into two dimensional maximum intensity projections using Image 
Pro 7.0. Cell spheroids were analyzed using an automated Image pro 7-based plugin to calculate surface 




Normal prostate (n=3) and primary prostate cancer specimens (n=21) were mounted on aminoacetylsilane-
coated glass slides (Starfrost, Berlin, Germany), deparaffinized in xylene and dehydrated in ethanol. Endoge-
nous peroxidase activity was blocked by 1% hydrogen peroxide in methanol for 20  min. Incubation with cit-
rate buffer was used for antigen retrieval. Slides were incubated with 1:500 dilution of Syk antibody (sc-
1077; Santa Cruz) overnight at 4°C, followed by chromogenic visualization using the EnVision DAKO kit 
(Dako, Glostrup, Denmark). After counterstaining with hematoxylin, slides were thoroughly washed, dehy-
drated, cleared in xylene and mounted in malinol (Chroma-Geselschaft, Körgen, Germany). 
Experimental bone metastasis assay
Male nude (BALB/c nu/nu) mice were anesthetized and injected with a single-cell suspension of 105 cells/
100  µl in PBS into the left cardiac ventricle. Outgrowth of spread PC3-M-Pro4luc cells was monitored weekly 
by whole body bioluminescent imaging (BLI) using an intensified charge-coupled device (I-CCD) video cam-
era of the in vivo Imaging System (IVIS100; Xenogen, Alameda, CA, USA) as described previously (1). Val-
ues are expressed as RLUs in photons/s. Bone metastases were also examined by Goldner staining after 
mice were sacrificed using decalcified bone. 
Flow cytometry
For flowcytometry, surface expression levels were determined using primary antibodies, followed by fluores-
cence-conjugated secondary antibodies, and analysis on a FACSCanto or sorting on a FACS Calibur (Bec-
ton Dickinson). 
Statistical analysis
Data are presented as mean ± SEM of at least 3 independent biological replicates unless otherwise stated. 
Student's t test (two-tailed) was used to compare groups. 
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One 7:e31281. 
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FIGURE S1. Whole organism automated bioimaging assay differentiates between androgen independent / metastatic and androgen-
dependent / non-metastatic  prostate cancer cells. (a) Representative  image of Casper fli- EGFP embryo 6 days following yolk sac 
implantation of 10µm fluorescent beads. Scale bar is 100µm for upper image, and 50µm for lower enlargement of area in inset. 
Passive spreading of beads was virtually undetectable and used as threshold for cancer cell dissemination. (b) Representative  image 
of C4-2B implanted embryos 6 days following xenotransplantation. Top, scale bar is 100 µm; middle, enlargement of inset, 
arrowheads point to disseminated tumor cells, scale bar is 50 µm; bottom, automated imaging and image analysis derived tumor foci 
– scale bar is 100 µm). (c) Scatter plots derived from automated imaging and image analysis of zebrafish xenografts with indicated 
cell lines 6 days following xenotransplantation in the yolk of Casper fli-EGFP embryos. Colors represent tumor cell foci detected in 
individual embryos. (d) Mean cumulative distance (MCD) determined from scatter plots represented in c for indicated cell lines using 
10µm fluorescent beads as negative control. Data from 2 independent experiments are combined. In total 5 embryos were 






FIGURE S2. SYK depletion attenuates PC3 dissemination  in zebrafish 
xenografts. Representative images of embryos implanted with PC3 
cells expressing indicated adenoviral shRNAs at 6 days following 






















1.5 FIGURE S3. Generation of stable 
lentiviral bulk-puromycin selected 
PC3 shSYK lines. qPCR analysis of 
SYK expression in PC3 cells stably 
expressing indicated lentiviral SYK 
shRNAs.



















FIGURE S4. SYK depletion attenuates PC3 3D ECM invasion. (a) Bright field images showing representative spheroids of PC3 cells 
expressing indicated lentiviral shRNAs at 6 days post-injection into collagen gels. Scale bar is 120µm. (b) PC3shSYK spheroid 6 days 
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b a ns ns ns ns FIGURE S5. SYK depletion does not downregulate integrin expression at 
mRNA level. qPCR analysis of integrin α2 
and β1 subunits in two independent 
lentiviral shSYK expressing PC3 lines
FIGURE S6. Silencing integrin α2β1 inhibits 3D ECM invasion and outgrowth of 
PC3 spheroids. (a) FACS analysis of surface expression of integrin subunits α2 
and β1 in PC3 cells expressing lentiviral shRNAs targeting indicated integrin 
subunits. (b) Quantification of expansion (mean spheroid area) and ECM invasion 
(MCD) for cell spheroids derived from control PC3 or PC3 expressing lentiviral 
shRNAs targeting integrin subunits measured at 6 days post-injection in collagen 
gels. (c) Representative images of cell spheroids analyzed for b (blue, Hoechst; 
red,Phalloidin). Scale bar is 120 µm.
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ABSTRACT
The receptor tyrosine kinase, MST1R has been implicated in prostate cancer growth and angiogenesis and, 
in this context; an important role has been attributed to MST1R expressed on tumor-associated macro-
phages. Here, we observed that MST1R expression in human prostate cancer cell lines correlates with 
androgen-independency and metastatic capacity. We expressed MST1R shRNAs in androgen-independent, 
metastatic PC3 cells. Bulk selected stable populations showed ~50% reduction in MST1R mRNA and pro-
tein surface expression. As a consequence, cell scattering in 2D and invasive outgrowth in 3D collagen matri-
ces was attenuated, which could be restored by HGF stimulation of the MST1R-related MET receptor. 
PC3shMST1R cells were also blocked in their ability to disseminate in a zebrafish embryo xenotransplanta-
tion model. Furthermore, RNAi targeting MST1R prevented the formation of bone metastases following in-
tracardiac inoculation in mice. Together, these findings demonstrate that down regulation of MST1R can in-
hibit prostate cancer invasion, dissemination and metastatic colonization.
INTRODUCTION
The macrophage stimulating 1 receptor (MST1R; RON; Met-related tyrosine kinase) is a receptor tyrosine 
kinase that has been implicated in various epithelial malignancies including breast, colon, ovarian, liver, and 
head and neck cancers (1-11). MST1R is also overexpressed in primary prostate cancer and at metastatic 
prostate cancer sites (12). Experiments using MST1R kinase-deficient mice have established a role for 
MST1R in prostate tumor growth and angiogenesis (13). Interestingly, this can be explained at least in part 
by a critical role for MST1R expression on macrophages in the tumor microenvironment (14). MST1R trans-
gene expression in prostate epithelium and findings from in vitro experiments indicate that MST1R ex-
pressed on prostate cancer cells could contribute to tumor cell survival, production of angiogenic chemoki-
nes, and tumor growth (12, 15). Importantly, while localized prostate cancer has an almost 100% survival 
rate, the occurrence of metastases in bone and other distant sites lowers 5-year survival to ~30%(16). 
MST1R has not been implicated in prostate cancer progression. The MST1R-related MET receptor stimu-
lates tumor growth and lymph node metastasis in a xenograft model using human PC3 prostate cancer cells 
(17) and HGF-MET signaling is an important target in prostate cancer progression (18). In this study, we 
took an RNAi-based approach to investigate the role of MST1R in several aspects of the prostate cancer 
metastatic cascade including cell migration, invasion, dissemination, and formation of bone metastases.
MATERIALS AND METHODS
Prostate cancer cell lines were obtained from ATCC and cultured according to the standard protocol. PC3-
M-Pro4luc cells have been described previously (19). Lentiviral shRNA constructs targeting MST1R 
(TRCN000012148; TRCN000012150) were obtained from the MISSION library (Sigma-Aldrich). Stable 
shRNA expressing PC3 and PC3-M-Pro4luc cells were bulk selected by puromycin. Generation of extracellu-
lar matrix (ECM)-embedded tumor cell spheroids was performed as previously described (20). Spheroid out-
growth and collagen invasion was quantified using an automated Image pro 7-based plugin to calculate sur-
face area of the spheroid, number of cells migrating into the collagen, and mean cumulative distance (MCD) 
travelled by these cells. Recombinant hepatocyte growth factor (HGF; Sigma) was used at 5 ng/ml. For ze-
brafish xenograft assays, CMDiI-labeled PC3 cells were injected in the yolk of 2-day-old fli-EGFP-casper em-
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bryos and fixed 6 days post-implantation as described previously (21). The automated process for collection 
of confocal image stacks, generation of in-focus composite images, alignment and orientation of the images, 
and subsequent quantification of tumor cell dissemination was done as described previously (21). Dissemina-
tion is described as mean cumulative distance (MCD) reflecting cumulative distance from the primary injec-
tion site of all tumor cells in each embryo, averaged over all embryos. Experimental bone metastasis in mice 
was analyzed by ~weekly whole body bioluminescent imaging (BLI) of nude mice following intracardiac injec-
tion with PC3-M-Pro4luc cells as described (19). Metastatic lesions in bone were identified by immunohisto-
chemistry. FACS and Western blot experiments were performed as described previously (22) using MET 
phospho-Tyr1349 (Cell Signaling) and tubulin (Sigma) antibodies. Data for all experiments are presented as 
mean ± SEM of at least 2 independent biological replicates. Student's t test (two-tailed) was used to com-
pare groups.
RESULTS AND DISCUSSION
We evaluated MST1R mRNA expression in a panel of prostate cancer cell lines. MST1R levels in cells re-
ported to be androgen-independent and metastatic in mice, including PC3 cells were 2-8 fold higher than 
levels found in androgen-dependent non-metastatic cells (Fig 1A). MST1R protein expression was also de-
tected in PC3 cells (Fig 1B). Likewise, in a series of human prostate cancer xenografts representing various 
aspects of human prostate cancer progression (23), MST1R mRNA levels were higher in most androgen-
independent xenografts as compared to androgen-dependent xenografts (Fig 1C).
Based on these expression data, we asked if MST1R plays a role in aspects of prostate cancer progression. 
To address this question, MST1R expression in PC3 cells was silenced using lentiviral shRNAs. In bulk 
puromycin-selected stable PC3 shRNA populations, two distinct shRNAs caused ~50% silencing MST1R 
expression (Fig 2A).
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FIGURE 1. MST1R expression on human prostate cancer cells. A: MST1R mRNA expression determined by qPCR in panel of human 
prostate cancer cell lines. AD, androgen-dependent; AI, androgen independent. B: Immuno-histochemical staining showing MST1R 
expression in PC3 cells. Right panel shows zoom-in of area marked by dotted line in left panel. Adapted from www.proteinatlas.org. C: 
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FACS analysis confirmed downregulation at the level of MST1R cell surface expression (Fig 2B). Interest-
ingly, reduced expression of MST1R caused a conversion from a completely scattered phenotype to more 
cohesive growth in 2D culture with formation of multicellular islands (Fig 2C). Moreover, when these cells 
were grown as spheroids in 3D collagen matrices, wild type- and PC3shctr cells were invasive whereas the 
number of cells migrating into the collagen was strongly reduced in PC3shMST1R cells (Fig 2D). Quantifica-
tion of spheroid area and cell migration in Phalloidin-stained 3D cultures demonstrated that MST1R silencing 
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FIGURE 2.MST1R expression supports invasive growth of human prostate cancer cells. A: Relative MST1R mRNA expression determined by 
qPCR in PC3 cells bulk puromycin selected for expression of indicated lentiviral shRNAs. B: FACS analysis of MST1R surface expression on 
PC3 cells expressing indicated lentiviral shRNAs. MFI, mean fluorescence intesity. C: Microphotographs of 2D cultures of PC3 cells expressing 
indicated lentiviral shRNAs. Dotted circles indicate cell islands observed in PC3shMST1R cells. D,E: Representative images (D) and 
quantification (E) of spheroid outgrowth and ECM invasion (mean cummulative distance from spheroid center of migrating cells, MCD) for 
Phalloidin-stained PC3 cells expressing indicated shRNAs 6 days post-injection in collagen gels. F: Microphotographs of 3D collagen-
embedded spheroids 6 days post-injection for PC3shctrl (upper) and PC3shMST1R cells in absence (lower, left) or presence of HGF (lower, 
right). G: Western blot showing MET phospho-Tyr1349 levels and tubulin (tub) loading control in PC3 cells expressing indicated shRNAs in 
absence or presence of HGF. Data are presented as mean ± s.e.m.; *p<0.05, ***p<0.001.
Scattering and invasion are stimulated by HGF binding to the MST1R-related MET receptor and this signal-
ing axis is a candidate drug target to halt prostate cancer progression (18). Cross talk between MST1R and 
MET has been shown to support the transforming potential of oncogenic MET mutants (24). To test if the at-
tenuated invasion caused by MST1R downregulation was due to inactivation of MET signaling 
PC3shMST1R were treated with HGF. HGF treatment could restore invasion of PC3shMST1R cells (Fig 2F). 
In agreement, MST1R silencing did not prevent MET phosphorylation in response to HGF (Fig 2G). To-
gether, this indicates that the level of downregulation of MST1R in PC3shMST1R cells attenuates invasion 
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FIGURE 3. MST1R expression on human prostate cancer cells supports dissemination in zebrafish xenotransplantation model. A:  Confocal 
microscopy images showing dissemination of PC3 cells expressing indicated MST1R shRNAs 6 days post implantation in yolk of Fli-GFP-
Casper zebrafish embryos. Red, CM-DiI-labeled tumor cells; green, GFP-marked endothelial cells. Arrow heads indicate PC3 cells 
disseminated to tail region. B: Scatter plot representation of dissemination of PC3 cells expressing indicated MST1R shRNAs. Colors represent 
individual embryos. N=number of injected embryos from 2 biological replicates. C: Mean cumulative distance (MCD) determined from data 
represented in B. Data are presented as mean ± s.e.m. *p<0.05, ***p<0.001.
These in vitro results indicated that enhanced levels of MST1R as observed in prostate cancer cells not only 
regulate tumor growth but also stimulate cell migration/invasion of prostate cancer cells in extracellular ma-
trix. To study effects on cell migration in vivo, we made use of zebrafish embryo xenografts. Here, a primary 
tumor is formed at the injection site and subsequent dissemination throughout the embryo is assessed 6 
days post-injection. The small size and optical transparency of zebrafish embryos and the use of transgenic 
strains with a fluorescently marked vasculature allows automated confocal imaging and image analysis to 
quantify dissemination in large numbers of embryos (21). Injected PC3 cells and PC3 cells expressing con-
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FIGURE 4. MST1R expression on human prostate cancer cells supports metastatic colonization in mouse experimental bone metastasis 
model. A: Relative MST1R RNA expression determined by qPCR in PC3-M-Pro4luc cells bulk puromycin selected for expression of indicated 
lentiviral shRNAs. B: Number of bone metastases per mouse determined by immunohistochemistry 40 days post intracardiac injection of 
100,000 PC3-M-Pro4luc cells expressing indicated lentiviral shRNAs. C: Total tumor burden determined by whole body BLI  at indicated time 
points post intracardiac injection of 100,000 PC3-M-Pro4luc cells expressing indicated lentiviral shRNAs. Inset shows tumor burden during the 
first 20 days. N=number of injected mice. Data are presented as mean ± s.e.m. *p<0.05, **p<0.005.
trol shRNA disseminated throughout the embryo with multiple tumor cell foci in the tail region (Fig 3A,B). By 
contrast, in agreement with the observed effect in PC3 migration/invasion in vitro, PC3shMST1R mostly re-
mained close to the area of injection and very few tumor cell foci were observed in the tail. In two independ-
ent shMST1R lines, reduced expression of MST1R significantly impaired dissemination in this model (Fig 
3A-C). Subsequently, we assessed if MST1R plays a role in later stages of prostate cancer metastasis that 
involve extravasation and homing and expanding in bone lesions. For this purpose, we silenced MST1R in 
the PC3-derived PC3-Pro4-luc cells (19) and analyzed stable bulk-selected shMST1R populations that had 
~70% reduction in MST1R expression (Fig 4A) in a preclinical mouse model for bone metastasis (19).  Fol-
lowing intracardiac injection  of control or shMST1R cells whole animal BLI was used to measure outgrowth 
of metastatic lesions over time and  immunohistochemistry of bone sections at the end of the experiment 
was used to determine the number of metastases. Mice injected with PC3 cells expressing a control shRNA 
showed on average ~ 2 bone metastases whereas very few metastatic lesions were detected in the bone of 
mice injected with PC3shMST1R cells (Fig 4B). In agreement, the total metastatic tumor burden determined 
by BLI was strongly suppressed as a consequence of the reduction in MST1R expression (Fig 4C,D).
In summary, our findings in 3D in vitro and preclinical in vivo models show that MST1R expression in human 
prostate cancer cells can support local invasion, dissemination, and formation of bone metastases. These 
results significantly extend earlier findings on the role of MST1R in prostate cancer formation. It has been 
previously established that MST1R supports prostate tumor growth and angiogenesis and this can involve 
MST1R expressed on prostate cancer cells as well as MST1R expressed on cells in the tumor microenviron-
ment (13-15). Our current report also implicates MST1R expressed on prostate cancer cells in aspects of 
prostate cancer metastasis. Altogether, the data from several studies indicate that MST1R represents an at-
tractive potential drug target for molecular targeted therapy.
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The complexity of a biological process such as metastasis necessitates that with our current technology dis-
crete steps of the problem are analyzed. We decided to focus our studies on androgen independent prostate 
cancer (AIPC), which is generally highly aggressive and metastatic. Reliable and well-characterized model 
systems of prostate cancer progression are of utmost importance to achieve the challenge of finding a cure 
especially for the AI stage of prostate cancer. The dream of molecular targeted therapies is that some day a 
patient’s own cells will be rapidly tested in vitro with a palette of therapeutic agents to find the one best 
suited to the patient’s specific needs (1). An obvious goal of tissue engineers and cancer modelers is to pro-
gress from good models of tissue complexity and function into models that can be standardized for drug 
screening purposes. In order to effectively hunt for targets in preclinical testing it is necessary to scale the 
reliable models for medium or high throughput screening (HTS) (1). Because of the technical challenges in-
volved, there are few accomplished metastasis models that have the ability to support HTS (1).
In order to meet this challenge, we worked in the direction of developing new models that recapitulate key 
steps in the metastatic cascade. We developed a 3D culture and a xenograft model to study growth, inva-
sion and dissemination. First, we developed a three-dimensional collagen matrix based spheroid assay of 
growth and invasion (chapter 2). This assay recapitulates the steps of growth and invasion of tumors at pri-
mary or metastatic sites. Collagen type 1 is one of the predominant matrix proteins in the bone, and hence 
the model provides an ideal environment to study the growth and invasion characteristics of the androgen 
independent metastatic prostate tumors. Furthermore, we adapted this model in 96 well plates and demon-
strated the applicability of this model in high throughput screening platforms. We also applied this method to 
cell suspensions derived from resection specimens, which opens the possibility to test therapeutic strategies 
on freshly isolated material from individual patients. So far, sarcoma biopsies were used; it remains to be es-
tablished whether this will also be successful for carcinomas, including prostate cancer. For the future, we 
would also like to adapt/expand this assay to study the complex interactions between tumor cells and stro-
mal cells including for instance endothelial cells, which could be achieved by injecting these spheroids to-
gether in one matrix. This could provide us novel information regarding the process of tumor induced neoan-
giogenesis or vasculogenesis, which could be further useful for the development of novel anti-angiogenic 
therapies against cancer. In addition, we have used PC3 cells to study prostate cancer invasion in this in vi-
tro model. A major challenge will be to modify the culture conditions such that also less aggressive prostate 
cancer cell lines could be studied in the same system for instance by modification of the ECM environment 
or inclusion of supportive stromal cells. Ultimately this could provide a 3D in vitro model that mimics more 
closely prostate cancer in patients. 
Secondly, we turned our attention to the zebrafish, which is proving to be an excellent whole animal based 
model to study tumor development, invasion, and the dynamics of the metastasis cascade. Several research 
groups have demonstrated successful xenotransplantation of human cancer cells of different origin in ze-
brafish, and have carried out in vivo assessment of invasiveness, tumor induced angiogenesis (2-6), meta-
static behavior (7-10) and response to anticancer therapies (2, 11-14). The small size, transparency and 
availability of various transgenic fluorescent zebrafish lines prompted us to couple this model to automated 
confocal imaging and image analysis (chapter 3). To the best of our knowledge, this assay represents the 
first ever semi-automated, quantitative whole organism based bio-imaging assay in a vertebrate that allows 
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analysis of dissemination of cancer cells in a high throughput manner. Further automation that is developed 
for the injection of embryos will further develop this pipeline into a fully automated system. With the contin-
ued development in the field of imaging technology and availability of novel transgenic zebrafish lines, It will 
also be extremely interesting to use our assay to xenotransplant cell lines expressing combinations of fluo-
rescent markers allowing quantification of apoptosis, proliferation and dissemination. Furthermore, incorpora-
tion of specific transgenic zebrafish lines expressing fluorescently labeled immune cells or tissues into our 
automated assay will provide us valuable information regarding the tumor cell and microenvironmental inter-
actions. There are also some outstanding questions on the use of zebrafish; what is the predictability of the 
zebrafish xenograft model for other (rodent) modes; to what extent do effects observed correlate with the 
effects of compounds seen in man; what is the predictability of the zebrafish with respect to the PK-PD 
(Pharmacokinetics-Pharmacodynamics) relationships(15)? These questions need to be urgently addressed 
to warrant use of this model in drug discovery/development pipelines.
In chapter 5, we expanded this assay further and xenotransplanted a panel of aggressive (AI) and non-
aggressive (AD) prostate cancer cell lines. Prostate cancer cell lines, which are known to be androgen-
independent and/or metastatic in mice (LNCaP-derived C4-2 and C4-2B; DU145 and PC3) showed en-
hanced dissemination in zebrafish embryos as compared to androgen-dependent non-metastatic cells 
(LNCaP). Our findings show that this assay closely reflects the results obtained in more expensive and 
much lower throughput assays such as rodent xenografts. Based on these data, zebrafish embryos provide 
a microenvironment that allows successful engraftment, proliferation and dissemination of AIPC cell lines. 
Therefore, this assay represents an ideal platform to screen for targets mediating invasion and dissemina-
tion of hormone refractory prostate cancer using RNA interference or compound screens.
Current treatment options for prostate cancer are often unsuccessful, and in chapter 4 we discuss some 
strategies for improvement. However, there is clear need for new drug targets to widen the possibilities for 
treatment. Discovery of such new targets has been the major goal of our work. Therefore, we used our ex-
perimental models to address the following questions:
To answer these questions we devised an adenoviral based RNAi screen for mediators of prostate cancer 
dissemination using our automated whole animal based zebrafish model of xenotransplantation (chapter 5). 
Based on this screen, we identify SYK as a kinase supporting human prostate cancer dissemination. In line 
with zebrafish and 3D models, depletion of SYK also led to a strong reduction in metastatic colonization of 
androgen independent prostate carcinoma cells in a preclinical mouse model for prostate cancer bone me-
tastasis. In the present xenotransplantation models, the study of human material grafted into the mouse has 
various limitations, including a compromised immune system, differences in species specificity of proteins 
and an inability to capture early events in tumorigenesis (16). The use of genetically engineered models 
(GEM) that mimic prostate cancer progression provides a possibility for further validation of candidate tar-
gets identified in our screen (17). Thus, a key next step in studying the role of SYK in prostate cancer pro-
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gression would be to silence or delete the SYK gene in the TRAMP (transgenic adenocarcinoma mouse 
prostate) model that recapitulates the pathophysiological features of the prostate cancer progression in hu-
mans (18). SYK has been implicated in lymphoid malignancies and appears to play opposing roles in differ-
ent solid tumors but has not been previously associated with prostate cancer (19). SYK is believed to act as 
an oncogene because of its ability to increase phosphorylated AKT, which may imply the involvement of 
PI3K (20, 21), which is a key molecule implicated in migration and chemotaxis of both tumor and endothelial 
cells (22). Phosphorylation of SYK at Tyr323 forms a docking site for the p85 subunit of PI3K (23). The effect 
of SYK depletion on PI3K or AKT activity has to be determined but our findings indicate that it is indeed the 
SYK kinase activity that supports prostate cancer invasion and dissemination: the effect of SYK knockdown 
on metastatic colonization is reversed by wild type but not kinase dead SYK expression; pharmacological 
inactivation of SYK using R-406 and BAY-61- 3606 recapitulated the effect of silencing the SYK gene in vitro 
and in zebrafish model of xenotransplantation. 
It will be important to study the effect of SYK inhibition also in the mouse model used by us and other pre-
clinical mouse models mentioned above. We found that SYK regulates surface expression of adhesion re-
ceptors at the posttranslational level. This is a potential underlying mechanism for the support of prostate 
cancer dissemination by SYK: decreased expression of two of these candidate targets of SYK, integrin 
alpha-2 and CD44 leads to similar defects as depletion of SYK. It has been previously shown that SYK can 
regulate turnover or transport of adhesion receptors in other cell types (23,24) through a mechanism requir-
ing ITAM-mediated SYK and AKT activation and inducing membrane translocation or stabilization of adhe-
sion receptors. Future experiments should further unravel the mechanism of action of SYK in this respect. 
SYK acts as an oncogene in lymphomas, chronic leukemias, gastric cancers, and – based on our findings – 
in prostate cancer. Paradoxically it appears to be a tumor suppressor in breast cancer : downregulation of 
SYK levels correlate with growth and invasion in the latter case. Importantly, the SYK gene undergoes alter-
native splicing and the apparent opposite roles of SYK in different cancers may be related to this (25). Most 
studies have not distinguished between global and splice isoform–specific increases in SYK expression. It is 
possible that differential expression of SYK (L) and SYK (S) may contribute to these disparate observations 
in different cancers. It will be important to extend our own studies to identifying which isoforms are ex-
pressed and upregulated with progression (25). 
Another gene that was identified in the RNAi screen was MST1R. This MET-related receptor tyrosine kinase 
has been previously implicated in prostate cancer growth and angiogenesis. Its function in prostate cancer 
growth at least in part can be explained by a need for MST1R in cancer-associated macrophages (26). Nev-
ertheless, two studies indicate that this receptor also plays a role on prostate cancer cells themselves (27, 
28). In chapter 6, we show that downregulation of MST1R leads to a phenotype that is also observed when 
MET (the receptor for HGF) is downregulated in different cancer cell types: cells appear less scattered and 
form epithelial islands. We show for the first time that MET and MST1R both regulate prostate cancer cell 
invasion/migration in 3D collagen, and MST1R downregulation also inhibits dissemination in the zebrafish 
model. An increasing number of basic, translational and clinical studies have shown the importance of MET 
in prostate cancer progression. MET is overexpressed in primary prostate cancers, and its expression is fur-
ther increased in bone metastases and is associated with the development of castrate-resistant disease. Be-
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cause of its importance as a therapeutic target, MET inhibitors have reached clinical trials for advanced, 
castrate-resistant prostate cancer (29). A robust pipeline of high-quality inhibitors targeting different aspects 
of MET activation is already being explored in phase II, III clinical trials across multiple tumor types. The 
best-known example is the ARQ-197, which has already reached the late phase of clinical development in 
various tumors including prostate cancer (30,31). 
In the screen that was the basis for chapter 5, two MET shRNAs did not significantly affect PC3 dissemina-
tion. Since levels of knockdown were not analyzed in this screen, this does not exclude a role for MET in 
PC3 dissemination in this model. In fact, based on the literature, effective stable knockdown of MET may 
well interfere with dissemination similar to silencing of MST1R. Notably, there is also evidence for extensive 
cross talk between MET and MST1R (32). To test if the attenuated invasion caused by MST1R downregula-
tion was due to inactivation of MET signaling, PC3shMST1R were treated with HGF. The fact that HGF treat-
ment restored invasion of PC3shMST1R cells shows that MET signaling was intact. 
In agreement, MST1R silencing did not prevent MET phosphorylation in response to HGF. Whether MST1R 
and MET signaling act in parallel and HGF-stimulated MET activity compensates for the loss of MST1R, or 
whether HGF-induced MET activation resulted in transphosphorylation of MST1R in our experiments as re-
ported earlier (33, 34) remains to be established. Importantly, as observed for SYK, MST1R is confirmed in 
the mouse model as an important player in the later stages of prostate cancer metastasis perhaps playing a 
role in extravasation or outgrowth in the bone metastatic niche. Moreover, MST1R expression correlates 
with androgen-independence / metastatic potential in a panel of cell lines indicating that it may serve as an-
other potential target in prostate cancer progression. As discussed above for SYK, further studies in the dif-
ferent prostate cancer mouse models will be required to further implicate MST1R in prostate cancer progres-
sion and metastasis. Our current study, in combination with work by others on its role in tumor growth, war-
rants investment in this direction.
In conclusion, the results from this thesis have contributed small pieces of knowledge to our overall under-
standing of the problem of prostate cancer metastasis. We have developed novel fluorescence bio-imaging 
based automated models to screen for novel candidate targets involved in prostate cancer metastasis. Utiliz-
ing these models and adopting a functional genomics based approach; we identified SYK as a novel regula-
tor of prostate cancer progression. We also identified functional involvement of MST1R in regulating the pro-
gression of prostate cancer. For  both of these targets, there is supporting human clinical data to validate our 
results in prostate cancer. Although much further insight is required in the mechanism of action of these ki-
nases as well as in their RNA expression levels, splicing, protein levels, and activity in human prostate can-
cers, this is reassuring: it shows that results obtained in these models may be applicable to humans.
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Metastasering is een complex biologisch proces, dat stapsgewijs geanalyseerd moet worden met behulp 
van de huidige technologie. We hebben besloten om onze studies te richten op androgeen-onafhankelijke 
(AI) prostaatkanker, die over het algemeen zeer agressief is. Een betrouwbaar en goed gekarakteriseerd 
modelsysteem van prostaatkanker progressie is van groot belang om een behandeling voor de androgeen-
onafhankelijk staat te ontwikkelen. Om effectief nieuwe geneesmiddelen te maken, is het nodig om 
betrouwbare modellen op te schalen voor medium of high throughput screening (HTS). Gezien de 
technische uitdagingen zijn er weinig modellen die de mogelijkheid voor HTS ondersteunen.
Om deze uitdaging aan te gaan , hebben wij gewerkt aan het ontwikkelen van nieuwe modellen die de belan-
grijkste stappen in de progressie van kanker  recapituleren. We hebben 3D sferoïde  en een xenograft- 
model ontwikkeld om groei , invasie en disseminatie van kanker cellen te bestuderen. Eerst hebben wij een 
3D collageen matrix sferoïde assay van groei en invasie ontwikkeld (hoofdstuk 2). Deze test recapituleert de 
stappen van groei en invasie van tumoren op de primaire of metastatische sites. Collageen type 1 is een 
van de belangrijkste extracellulaire matrix (ECM) eiwitten in het bot , en is een ideale omgeving om de groei 
en invasie kenmerken van de androgeen-onafhankelijke metastaserende prostaatkanker te bestuderen. Dit 
model hebben wij toegepast in 96 wells platen waardoor het toepasbaar is voor high throughput screening. 
Vervolgens is dit model  toegepast voor celsuspensies verkregen uit resectiepreparaten. Het laatste opent 
de mogelijkheid om therapeutische strategieën op vers geïsoleerde materiaal van individuele patiënten te 
testen . Tot zover werden sarcoom biopten gebruikt , het is nog onbekend of deze ook succesvol zijn voor 
carcinomen, waaronder prostaatkanker. Voor de toekomst zouden wij graag deze assay willen uitbreiden/
toepassen om complexe interacties tussen tumorcellen en stromale cellen te bestuderen, bijvoorbeeld door 
injectie van combinaties van kanker -, endotheel, fibroblastcellen. Dit zou ons nieuwe informatie kunnen 
opleveren over het proces van tumor geïnduceerde neo-angiogenese of vasculogenese, dit kan vervolgens 
weer van belang zijn voor de ontwikkeling van nieuwe anti - angiogene therapieën tegen kanker. Wij hebben 
vooral gebruik gemaakt van PC3 cellen om prostaatkanker invasie in het in-vitro model te bestuderen. Een 
grote uitdaging zal zijn om de kweekomstandigheden zodanig aan te passen dat ook minder agressieve 
prostaatkanker cellijnen kunnen worden bestudeerd in hetzelfde systeem, bijvoorbeeld door wijziging van de 
ECM omgeving.
Ten tweede, richtten wij onze aandacht op de zebravis. Deze blijkt een goed diermodel te zijn om de ontwik-
keling van tumoren, de invasie, en de dynamiek van de metastaseringscascade te bestuderen. Verschil-
lende onderzoeksgroepen hebben succesvol xenotransplantatie van menselijke kankercellen van verschil-
lende oorsprongen in de zebravis uitgevoerd om deze processen te bestuderen zoals invasie; tumor geïn-
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duceerde angiogenese, experimentele metastasering en de respons op  anti-kanker therapieën. Het kleine 
formaat, transparantie en de beschikbaarheid van verschillende transgene zebravis fluorescerende lijnen 
hebben geleid tot koppeling van dit model aan geautomatiseerde confocale beeldvorming en beeldanalyse 
(hoofdstuk 3). Tot zo ver bekend, is dit de eerste semiautomatische bio-imaging assay gebaseerd op het 
hele organisme dat de analyse van de disseminatie van kankercellen in een high throughput manier moge-
lijk maakt. De volgende stap is de ontwikkeling van geautomatiseerde injectie van de cellen in het embryo 
zodat het een volledig geautomatiseerd systeem wordt. Door de voortdurende ontwikkeling op het gebied 
van imaging technologie en de beschikbaarheid van nieuwe transgene zebravis lijnen, zal het ook zeer inter-
essant zijn om onze test te gebruiken voor  kankercellijnen waarin combinaties van fluorescente markers 
worden gebruikt in kwantificering van apoptose, proliferatie en disseminatie.  In onze assay kunnen ook 
specifieke transgene zebravis lijnen gebruikt worden die fluorescent gelabelde immuuncellen of andere 
celtypen bevatten. Dit zal ons waardevolle informatie over de tumorcel en de micro-omgeving interacties 
opleveren. Er zijn enkele belangrijke openstaande vragen over het gebruik van de zebravis: wat is de voor-
spelbaarheid van het model voor gedrag in zoogdiermodellen; in welke mate correleren de effecten met de 
effecten in de mens; wat is de voorspelbaarheid van de zebravis met betrekking tot de PK - PD (Farmacoki-
netiek - Farmacodynamiek) relaties ? Deze vragen moeten dringend worden beantwoordt om de inzetbaar-
heid van dit geautomatiseerde  in vivo model in de geneesmiddelindustrie te realiseren.
In hoofdstuk 5, is het zebravis xenotransplantatie model toegepast op een een panel van agressieve (AI) en 
minder agressieve (androgeen afhankelijk; AD) prostaatkanker cellijnen. AI cellen toonden meer verspreid-
ing in zebravis embryo’s ten opzichte van AD cellen (LNCaP). Onze bevindingen tonen aan dat deze assay 
correleert met de resultaten van duurdere en low throughput assays zoals muismodellen. Op basis van deze 
gegevens, kunnen wij concluderen dat  zebravis embryo’s een passende omgeving leveren voor de succes-
volle implantatie, proliferatie en verspreiding van AI cellijnen. Daarom representeert deze test een ideaal plat-
form voor het screenen  van genen die zijn betrokken bij de invasie en disseminatie van AI prostaat kanker 
met behulp van RNA interferentie. Huidige behandelingsopties voor prostaatkanker zijn vaak niet succesvol 
en in hoofdstuk 4 bespreken we een aantal huidige strategieën voor verbetering. Echter, er is duidelijk be-
hoefte aan nieuwe drug targets om de mogelijkheden voor behandeling te verruimen. 
De ontwikkelde experimentele modellen zijn dan ook gebruikt om de volgende vragen te beantwoorden :
Kunnen wij onze modellen gebruiken om kritische targets te identificeren en valideren  die betrokken 
zijn bij prostaatkanker metastasering?
Kunnen we deze targets valideren in andere modellen?
Zijn deze targets relevant voor de menselijke situatie?
Om deze vragen te beantwoorden hebben wij een adenovirale RNAi screen uitgevoerd in het zebravis xeno-
transplantatie model om nieuwe targets voor prostaat kanker progressie te identificeren en valideren 
(hoofdstuk 5). Op basis van deze screen hebben wij het SYK kinase geïdentificeerd die betrokken is bij dis-
seminatie van de AI prostaatkankercellen. In lijn met de zebravis en 3D modellen leidt downregulatie  van 
SYK ook tot een sterke vermindering van metastatische kolonisatie in een preklinisch muismodel voor 
prostaatkanker bot metastasering. Dit model heeft belemmeringen zoals een gecomprimeerd immuunsys-
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teem, mogelijke effecten van muis-humaan combinatie, en het onvermogen om de eerste stappen van tu-
morgroei, invasie, en disseminatie te bestuderen. Het gebruik van genetisch gemanipuleerde modellen 
(GEM) die de progressie van prostaatkanker recapituleert biedt de mogelijkheid voor verdere validatie van 
de kandidaat- targetgenen  geïdentificeerd in onze screen. De volgende stap is bijvoorbeeld om de rol van 
SYK in prostaatkanker progressie te bestuderen door het SYK gen uit te schakelen in het TRAMP model 
dat de pathofysiologische kenmerken bij het vorderen van prostaatkanker in de mens recapituleert . De 
betrokkenheid van SYK is al aangetoond bij lymfoïde maligniteiten en lijkt tegengestelde rollen te spelen in 
verschillende solide tumoren. Tot zover bekend is, is SYK niet eerder verbonden aan prostaatkanker.
Het effect van SYK depletie op bekende downstream targets als PI3K of AKT activiteit moet worden be-
paald. Maar uit onze bevindingen blijkt wel al dat SYK kinase activiteit de prostaatkanker invasie, dissemina-
tie en metastatische kolonisatie  ondersteunt : Het effect van SYK downregulatie op metastatische kolonisa-
tie wordt teniet gedaan door expressie van wild type SYK maar niet door een “kinase-dode” mutant. Inder-
daad, recapituleert farmacologische remming van SYK activiteit met R-406 en BAY-61-3606 het effect van 
de SYK downregulatie in vitro en in het zebravis xenotransplantatie model. Het zal belangrijk zijn om het ef-
fect van farmacologische remming van SYK activiteit ook te bestuderen in het muismodel zoals gebruikt 
door ons en de andere bovengenoemde preklinische muismodellen. Verder hebben wij ook gevonden dat 
SYK de oppervlakte-expressie van adhesie receptoren, zoals CD44 en α2β1 integrine reguleert op het post 
translationele niveau. Dit zou een mogelijk onderliggende mechanisme zijn voor de rol van SYK in  de dis-
seminatie van prostaatkanker. siRNA downregulatie van het integrine of CD44 leidt eveneens tot ver-
minderde invasie of bot kolonisatie. Het is eerder aangetoond in andere celtypen dat SYK het transport en 
stabilisatie van adhesie receptoren door ITAM - gemedieerde SYK en AKT activatie- reguleert. Toekomstige 
experimenten moeten verder het mechanisme van de werking van SYK ontrafelen. SYK fungeert in prostaat-
kanker mogelijk als een oncogen, net als bij verschillende andere maligniteiten zoals lymfomen, chronische 
leukemie en maagkanker. In tegenstelling lijkt SYK op een tumor suppressor in borstkanker, waar downregu-
latie van SYK is gecorreleerd met groei en invasie. Belangrijk zou kunnen zijn dat het SYK gen alternatieve 
splicing ondergaat. De meeste studies hebben geen onderscheid gemaakt tussen globale en splice-
specifieke SYK expressie. Het is mogelijk dat differentiële expressie van SYK(L)  en SYK(S) de zo verschil-
lende functies in verschillende vormen van kanker verklaart. Het zal belangrijk zijn om onze eigen studies uit 
te breiden met de identificatie van de SYK isovormen.
Een ander gen dat wij hebben geïdentificeerd in onze screen is MST1R. Deze MET- gerelateerde receptor 
tyrosine kinase is al eerder aangetoond voor betrokkenheid bij groei en tumor geïnduceerd angiogenese bij 
prostaatkanker. De functie van MST1R in groei van prostaat tumor kan onder andere  ondersteunt  worden 
door MST1R in kanker - geassocieerde macrofagen. Twee studies laten zien dat deze receptor ook een rol 
speelt in de prostaatkankercellen. In hoofdstuk 6 laten wij zien dat downregulatie van MST1R leidt tot een 
fenotype dat ook wordt waargenomen wanneer MET (de receptor voor HGF) down gereguleerd wordt in ver-
schillende typen kankercellen. Cellen lijken minder verspreid en vormen epitheliale eilanden. Deze rol voor 
MST1R in invasie en migratie van prostaatkanker cellen is nieuw. Naast migratie in 3D collageen matrix 
bevordert MST1R de disseminatie van prostaatkanker cellen  in het zebravis embryo xenotransplantatie 
model en in de muis xenograft. Fundamenteel, translationeel en klinisch onderzoek heeft het belang van 
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MET aangetoond bij prostaatkanker progressie. MET komt verhoogd voor bij primaire prostaatkanker, en de 
MET expressie wordt verder verhoogd in bot metastasen en wordt geassocieerd met de ontwikkeling van 
castratie resistente  prostaatkanker. Vanwege het therapeutische belang, werden MET remmers al gebruikt 
in klinische studies voor behandeling van geavanceerde  castratie-resistente prostaatkanker. Een robuuste 
pijplijn van MET inhibitoren gericht op verschillende aspecten van de MET activering wordt al onderzocht in 
fase II en fase III klinische studies. Het bekendste voorbeeld is de ARQ-197, dat reeds de late fase van 
klinische ontwikkeling in verschillende tumoren heeft bereikt, waaronder prostaatkanker. Overigens bevatte 
de in hoofdstuk 5 beschreven screen twee MET shRNAs. Die vertoonden geen significant effect op de dis-
seminatie van de PC3 cellen. Aangezien het niveau van knockdown niet is  geanalyseerd in de screen kun-
nen we over de “non-hits” geen uitspraak doen en betekent dit zeker niet dat een rol voor MET is uitgesloten 
in de disseminatie van de PC3 cellen in dit model. In feite zou gebaseerd op de literatuur, effectieve stabiele 
knockdown van MET een hetzelfde effect moeten hebben op disseminatie van prostaatkanker cellen als de 
MST1R knockdown. Er is ook bewijs voor een functionele interactie tussen MET en MST1R. Ons onderzoek 
wijst er tot dusver niet op dat MST1R downregulatie een effect op MET signalering heeft maar in het licht 
van de beschreven cross-fosforylatie zou dit zou verder onderzocht kunnen worden. Belangrijk is dat 
MST1R, net als SYK, wordt bevestigd in het muismodel. Bovendien laten AI lijnen een hogere expressie 
zien van MST1R. Zoals hierboven genoemd voor SYK, zullen verdere studies in de verschillende prostaat-
kanker muismodellen van belang zijn om MST1R te betrekken bij prostaatkanker progressie. Onze huidige 
studie waarin MST1R in migratie, invasie van prostaatkanker cellen wordt geïmpliceerd is een eerste stap in 
deze richting.
Tot slot hebben de resultaten van dit proefschrift bijgedragen aan ons algemeen begrip van het probleem 
van prostaatkanker metastase. We hebben nieuwe op fluorescentie bio-imaging gebaseerde geautoma-
tiseerde modellen ontwikkeld om te detecteren welke kandidaat genen betrokken zijn bij prostaatkanker me-
tastasering. Gebruikmakend van deze modellen konden we SYK en MST1R identificeren als nieuwe regula-
toren van prostaatkanker progressie. Voor beide potentiele drug-targets hebben we een eerste stap gezet 
voor validatie in humane prostaatkanker. Hoewel dit sterk moet worden uitgebreid en verder onderzoek no-
dig is naar hun werkingsmechanisme en regulatie van RNA expressie/ splicing/ eiwit niveaus, zijn de resul-
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